[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 235
1. Bortolin MT, Zanussi S, Talamini R, Simonelli C, Pratesi C, Tedeschi R, Abbruzzese L, Manuele R, Rupolo M, Tirelli U, De Paoli P: Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT). AIDS Res Hum Retroviruses; 2010 Feb;26(2):245-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT).
  • The kinetics and predictive value of HIV-1 DNA (HIV DNA) levels in relapsed or refractory HIV lymphoma patients, treated with high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT), were investigated.
  • HIV DNA was measured by real-time PCR in the peripheral blood mononuclear cells (PBMCs) of 22 patients observed for a median follow-up of 31.0 months.
  • At baseline, HIV DNA was found to be correlated with HIV-1 RNA (HIV RNA) (r = 0.56), but not with CD4(+) counts (r = -0.10).
  • HIV RNA load was under control for the entire follow-up, while HIV DNA levels were almost always detectable (baseline levels vs. 1 year from ASCT levels, p > 0.05).
  • Baseline HIV DNA levels were significantly different between alive and deceased patients (p = 0.03), and the overall survival (OS) analysis showed that for patients with higher HIV DNA levels at baseline there was a higher and nearly significant risk of death if compared to patients with lower levels (HR, 8.33, 95% CI, 0.99-70.06, p = 0.05).
  • Our study demonstrated that high HIV DNA levels at baseline could predict overall survival after ASCT in one of the largest cohorts of HIV lymphoma patients treated with salvage therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. DNA, Viral / blood. HIV-1 / isolation & purification. Lymphoma, AIDS-Related / mortality. Stem Cell Transplantation. Viral Load


2. Tarantul VZ: Virus-associated lymphomagenesis. Int J Biomed Sci; 2006 Jun;2(2):101-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virus-associated lymphomagenesis.
  • Lymphomas are one of the best studied cancer types closely associated with a small but definite range of viruses.
  • Numerous data show a close interrelation between lymphomagenesis and infection by such viruses as Kaposi's sarcoma herpesvirus (KSHV), Epstein-Barr virus (EBV), hepatitis C virus (HCV), human T-cell leukemia virus (HTLV), and human immunodeficiency virus (HIV).
  • For instance, experiments on monkeys artificially infected with viruses and data on anti-cancer effect of specific antiviral preparations strongly suggest the involvement of viruses in lymphoma development.
  • The present review is devoted to the association of different viruses with human lymphomas and to viral genes potentially involved in the neoplastic process.
  • The recognition of virus involvement in lymphomagenesis may facilitate new strategies for cancer therapy, diagnosis and screening and can lead to a reduction in the number of individuals at risk of disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23674972.001).
  • [ISSN] 1550-9702
  • [Journal-full-title] International journal of biomedical science : IJBS
  • [ISO-abbreviation] Int J Biomed Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3614592
  • [Keywords] NOTNLM ; HIV / HIV virus HIV / epstein-barr virus / epstein-barrvirus / hepatitis b virus / hepatitis cvirus / herpesvirus / lymphoma / oncogenicity / virus
  •  go-up   go-down


3. Folk GS, Abbondanzo SL, Childers EL, Foss RD: Plasmablastic lymphoma: a clinicopathologic correlation. Ann Diagn Pathol; 2006 Feb;10(1):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: a clinicopathologic correlation.
  • Plasmablastic lymphoma (PBL) is an uncommon, recently described B-cell-derived lymphoma that displays distinctive affinity for extranodal presentation in the oral cavity.
  • Plasmablastic lymphoma is strongly associated with human immunodeficiency virus (HIV) infection, but has been reported in HIV-negative individuals.
  • Plasmablastic lymphoma may be poorly recognized by pathologists, which is partly attributable to its relatively rare occurrence and unusual immunophenotype.
  • Five cases of oral cavity lymphomas conforming to the current World Health Organization morphological criteria for PBL were retrieved from the consultation files at the Armed Forces Institute of Pathology.
  • Follow-up revealed only 1 patient alive with no evidence of disease.
  • Our cases show that PBL is an aggressive type of B-cell lymphoma predominantly found in the oral cavity.
  • Plasmablastic lymphoma is often associated with HIV infection.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology. Mouth / pathology. Mouth Neoplasms / pathology. Plasma Cells / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16414538.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


Advertisement
4. Hassan A, Kreisel F, Gardner L, Lewis JS Jr, El-Mofty SK: Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status. Head Neck Pathol; 2007 Dec;1(2):150-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status.
  • Plasmablastic lymphoma (PBL) is a rare acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma (AIDS-NHL), with predilection for the mucosa of oral cavity.
  • It usually has a plasmablastic morphology, expressing plasma cell-associated antigens with weak or absent expression of B-cell-associated markers.
  • To further define the immunophenotypic and molecular genetics of these tumors, we investigated two cases of plasmablastic lymphomas of the head and neck for c-myc gene rearrangement and immunoglobulin heavy chain (IgV(H)) hypermutation status.
  • For the first time we report a case of AIDS-related PBL that, by fluorescence in situ hybridization (FISH), shows a c-myc gene rearrangement.
  • Although current literature suggests that most cases of c-myc gene rearranged AIDS-NHL are Burkitt's lymphoma, our case has an immunophenotype characteristic for PBL.
  • The concurrent B-cell immunophenotype of BCL-6(-)/CD138(+)/MUM-1(+) also suggests a post-germinal center B-cell origin of this lymphoma.
  • [MeSH-major] Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Mouth Neoplasms / pathology. Proto-Oncogene Proteins c-myc / genetics

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):77-81 [15621784.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Cancer. 2005 Jun 25;105(3):139-44 [15803491.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Aug;100(2):198-206 [16037778.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):96-102 [11755827.001]
  • [Cites] Hum Pathol. 2002 Apr;33(4):392-404 [12055673.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3928-32 [14581416.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):95-100 [9709310.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Blood. 1993 Jan 1;81(1):166-76 [8380252.001]
  • [Cites] Blood. 1993 Jul 15;82(2):552-63 [8392399.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):67-82 [9044511.001]
  • (PMID = 20614267.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ PMC2807524
  • [Keywords] NOTNLM ; Acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphoma / Immunoglobulin variable heavy chain hypermutation status / Plasmablastic lymphoma / c-myc gene rearrangement
  •  go-up   go-down


5. Marimo C: Epidemiology of oral Kaposi's sarcoma in Zimbabwe 1988-1997: a population-based study. Cent Afr J Med; 2008 Jan-Apr;54(1-4):15-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Sub-Saharan Africa has the highest number of HIV/AIDS cases globally which contrasts with the lack of population-based studies of oral Kaposi's sarcoma (OKS); one of the clinical cardinal signs of HIV/AIDS.
  • To date, no study has investigated the incidence of OKS in African populations affected by the HIV/AIDS epidemic.
  • Among AIDS-associated malignancies, OKS accounted for 98% while the balance comprised Burkitt's lymphoma, Hodgkin's and Non-Hodgkin's lymphomas, haemangiosarcoma and lymphoma not specified.
  • These findings are attributable to the high human immunodeficiency virus infection (HIV) rates recorded for

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21644423.001).
  • [ISSN] 0008-9176
  • [Journal-full-title] The Central African journal of medicine
  • [ISO-abbreviation] Cent Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Zimbabwe
  •  go-up   go-down


6. Ho SF, Fink C, Murray PI: Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma. Ocul Immunol Inflamm; 2005 Dec;13(6):471-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma.
  • We report an HIV-positive patient who developed a unilateral retinitis and subsequent intracranial lesions.
  • The finding of Epstein Barr virus (EBV) DNA at a > 1-log greater concentration in the vitreous compared to blood raised the possibility of a primary CNS non-Hodgkin's lymphoma, which was subsequently confirmed on brain biopsy.
  • [MeSH-major] DNA, Viral / genetics. Herpesvirus 4, Human / genetics. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321894.001).
  • [ISSN] 0927-3948
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


7. Sirianni MC, Campagna M, Scaramuzzi D, Carbonari M, Toschi E, Bacigalupo I, Monini P, Ensoli B: Control of human herpes virus type 8-associated diseases by NK cells. Ann N Y Acad Sci; 2007 Jan;1096:37-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Control of human herpes virus type 8-associated diseases by NK cells.
  • NK cell activity is reduced during disease progression in human immunodeficiency virus (HIV) infection, and in individuals with AIDS-associated tumors linked with infection by the oncogenic human herpes virus type-8 (HHV8), including Kaposi's sarcoma (KS) and primary effusion lymphomas (PEL).
  • We have demonstrated that AIDS-related KS (AIDS-KS) is characterized by an increased expression of inhibitory receptors by T lymphocytes, and that HIV-non-infected patients with KS (classic KS, C-KS) have a substantial number of NK cells bearing these same receptors.
  • However, the cytotoxic activity of NK cells is reduced in patients with C-KS, AIDS-KS, or PEL patients, who are all infected by the HHV8, and this correlates with disease severity.
  • Since PEL cells express the same HHV8 latency program as KS cells, these data point to MHC-I downregulation by HHV8 as a primary immune evasion mechanism against CTL responses, further reinforced by upregulation of inhibitory receptors on T and NK cells in the setting of HIV and/or HHV8 infection.
  • Thus, studies on killing receptor regulation and signaling in T and NK cells may shed light on the pathogenesis of HHV8-associated tumors both in HIV-infected or -noninfected patients.
  • [MeSH-minor] Cytotoxicity, Immunologic. HIV Infections / complications. HIV Infections / therapy. Histocompatibility Antigens Class I / metabolism. Humans. Immune System. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / virology. Signal Transduction. T-Lymphocytes / metabolism. T-Lymphocytes, Cytotoxic / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405914.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


8. Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA, Cullen BR: Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol; 2010 Nov;84(22):11670-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LCL formation serves as a model for lymphomagenesis, and LCLs are phenotypically similar to EBV-positive diffuse large B-cell lymphomas (DLBCLs), which represent a common AIDS-associated malignancy.
  • B-cell infection by EBV induces the expression of several cellular microRNAs (miRNAs), most notably miR-155, which is overexpressed in many tumors and can induce B-cell lymphomas when overexpressed in animals.
  • In contrast, three other B-cell lymphoma lines, including two EBV-positive Burkitt's lymphoma cell lines, grew normally in the absence of miR-155 function.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2006 Jun;80(11):5321-6 [16699012.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]
  • [Cites] J Gen Virol. 2006 Oct;87(Pt 10):2885-90 [16963746.001]
  • [Cites] Science. 2007 Apr 27;316(5824):604-8 [17463289.001]
  • [Cites] Science. 2007 Apr 27;316(5824):608-11 [17463290.001]
  • [Cites] Nucleic Acids Res. 2007;35(10):e73 [17478510.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1156-61 [17487835.001]
  • [Cites] Nat Methods. 2007 Sep;4(9):721-6 [17694064.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]
  • [Cites] Immunity. 2007 Dec;27(6):847-59 [18055230.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Feb;181(1):8-15 [18262046.001]
  • [Cites] J Pathol. 2008 May;215(1):13-20 [18348159.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2128-36 [17968323.001]
  • [Cites] Nat Biotechnol. 2008 Apr;26(4):407-15 [18392026.001]
  • [Cites] J Virol. 2008 Jun;82(11):5295-306 [18367535.001]
  • [Cites] Immunity. 2008 May;28(5):621-9 [18450484.001]
  • [Cites] Immunity. 2008 May;28(5):630-8 [18455451.001]
  • [Cites] Oncogene. 2008 Jul 17;27(31):4373-9 [18372920.001]
  • [Cites] Nature. 2008 Aug 7;454(7205):780-3 [18596690.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8164-72 [18829576.001]
  • [Cites] J Virol. 2008 Nov;82(21):10436-43 [18753206.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Dec 12;377(2):579-83 [18926796.001]
  • [Cites] Nucleic Acids Res. 2008 Nov;36(20):6608-19 [18940871.001]
  • [Cites] J Virol. 2008 Dec;82(24):12213-20 [18842708.001]
  • [Cites] Virology. 2008 Dec 20;382(2):257-66 [18950829.001]
  • [Cites] J Virol. 2009 Jan;83(1):489-92 [18945769.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] J Virol. 2009 Apr;83(7):3333-41 [19144710.001]
  • [Cites] Leukemia. 2009 Apr;23(4):807-10 [18987659.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7113-8 [19359473.001]
  • [Cites] Genes Dev. 2009 May 15;23(10):1151-64 [19451215.001]
  • [Cites] J Virol. 2009 Dec;83(23):12009-17 [19759154.001]
  • [Cites] RNA Biol. 2009 Nov-Dec;6(5):541-5 [19901530.001]
  • [Cites] J Virol. 2010 Jan;84(2):695-703 [19889781.001]
  • [Cites] EMBO Mol Med. 2009 Aug;1(5):288-95 [19890474.001]
  • [Cites] Science. 2010 Jan 8;327(5962):198-201 [19965718.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3111-6 [20133617.001]
  • [Cites] Cell. 2010 Apr 2;141(1):129-41 [20371350.001]
  • [Cites] J Virol. 2010 May;84(10):5229-37 [20219912.001]
  • [Cites] J Virol. 2010 Jul;84(13):6318-27 [20427544.001]
  • [Cites] Mol Cell. 2002 Jun;9(6):1327-33 [12086629.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]
  • [Cites] Nature. 1988 Sep 8;335(6186):181-3 [3412474.001]
  • [Cites] Mol Cell Biol. 1989 Jun;9(6):2657-64 [2548084.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):103-6 [16175574.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Feb;45(2):147-53 [16235244.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]
  • (PMID = 20844043.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI007392; United States / NIAID NIH HHS / AI / P30-AI045008; United States / NIAID NIH HHS / AI / R01-AI067968; United States / NIAID NIH HHS / AI / R01 AI067968; United States / NCI NIH HHS / CA / T32-CA0009111; United States / NIAID NIH HHS / AI / P30 AI045008; United States / NCI NIH HHS / CA / T32 CA009111; United States / NIAID NIH HHS / AI / T32-AI007392; United States / NCI NIH HHS / CA / K99 CA137860-01A1; United States / NCI NIH HHS / CA / K99 CA137860; United States / NCI NIH HHS / CA / K99-CA137860
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN155 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2977875
  •  go-up   go-down


9. Navarro WH, Kaplan LD: AIDS-related lymphoproliferative disease. Blood; 2006 Jan 1;107(1):13-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphoproliferative disease.
  • Not long after the recognition of HIV as the causative agent of AIDS, it was evident that individuals infected with HIV developed lymphoma at a greater rate than the population at large.
  • Approximately two thirds of AIDS-related lymphoma (ARL) cases are categorized as diffuse large B-cell type, with Burkitt lymphomas comprising 25% and other histologies a much smaller proportion.
  • Typically, these individuals have presented with advanced extranodal disease and CD4+ lymphocyte counts of less than 200/mm3.
  • Coinfection with other viruses such as Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus have led to the genesis of previously rare or unrecognized lymphoma subtypes such as plasmablastic and primary effusion lymphomas.
  • Significant progress has been made in the understanding and management of ARL but outcomes still remain inferior compared to those achieved in HIV- individuals.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099881.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 100
  •  go-up   go-down


10. Corti M, Villafañe MF, Trione N, Schtirbu R, Narbaitz M: Primary pulmonary AIDS-related lymphoma. Rev Inst Med Trop Sao Paulo; 2005 Jul-Aug;47(4):231-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary AIDS-related lymphoma.
  • Extranodal involvement is common in lymphomas associated with human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS).
  • However, primary pulmonary AIDS-related non-Hodgkin's lymphoma is very rare and only few reports were published in the medical literature.
  • Primary pulmonary lymphoma associated with AIDS is generally a high-grade B-cell non-Hodgkin lymphoma and Epstein-Barr virus is strongly associated with the pathogenesis of these tumors.
  • We report a patient with AIDS and primary pulmonary lymphoma which clinical presentation was a total atelectasis of the left lung.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Pulmonary Atelectasis / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16138208.001).
  • [ISSN] 0036-4665
  • [Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo
  • [ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


11. Stevenson GT: CD38 as a therapeutic target. Mol Med; 2006 Nov-Dec;12(11-12):345-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CD38 molecule is well represented on cell surfaces in many cases of a variety of lymphoid tumors, notably multiple myeloma, AIDS-associated lymphomas, and post-transplant lymphoproliferations.
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Cell Line, Tumor. Humans. Leukemia / immunology. Lymphoma, B-Cell / immunology. Mice. Mice, SCID. Multiple Myeloma / immunology. Transplantation, Heterologous

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2001 Jan;25(1):1-12 [11137554.001]
  • [Cites] Mol Cancer Ther. 2004 Mar;3(3):345-52 [15026555.001]
  • [Cites] Scand J Immunol. 1978 Apr;7(4):297-306 [418499.001]
  • [Cites] Am J Hematol. 1990 Feb;33(2):101-9 [2301368.001]
  • [Cites] Blood. 1991 Mar 1;77(5):1071-9 [1995092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):352-6 [8380497.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1442-9 [7520771.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3017-25 [7524764.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1762-9 [15905193.001]
  • [Cites] Leuk Res. 2007 Apr;31(4):455-63 [16920192.001]
  • (PMID = 17380203.001).
  • [ISSN] 1076-1551
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; EC 3.2.2.5 / Antigens, CD38
  • [Other-IDs] NLM/ PMC1829201
  •  go-up   go-down


12. Mwakigonja AR, Kaaya EE, Mgaya EM: Malignant lymphomas (ML) and HIV infection in Tanzania. J Exp Clin Cancer Res; 2008;27:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphomas (ML) and HIV infection in Tanzania.
  • BACKGROUND: HIV infection is reported to be associated with some malignant lymphomas (ML) so called AIDS-related lymphomas (ARL), with an aggressive behavior and poor prognosis.
  • The ML frequency, pathogenicity, clinical patterns and possible association with AIDS in Tanzania, are not well documented impeding the development of preventive and therapeutic strategies.
  • Available sera from 38 ML patients were screened (ELISA) for HIV antibodies.
  • RESULTS: The proportion of ML out of all diagnosed tumors at MNH during the 6 year period was 4.2% (176/4200) comprising 77.84% non-Hodgkin (NHL) including 19.32% Burkitt's (BL) and 22.16% Hodgkin's disease (HD).
  • The ML tumors frequency increased from 0.42% (1997) to 0.70% (2001) and 23.7% of tested sera from these patients were HIV positive.
  • Supra-diaphragmatic presentation was commonest and histological sub-types were mostly aggressive B-cell lymphomas however, no clear cases of primary effusion lymphoma (PEL) and primary central nervous system lymphoma (PCNSL) were diagnosed.
  • CONCLUSION: Malignant lymphomas apparently, increased significantly among diagnosed tumors at MNH between 1996 and 2001, predominantly among the young, HIV infected and AIDS patients.
  • The frequent aggressive clinical and histological presentation as well as the dominant B-immunophenotype and the HIV serology indicate a pathogenic association with AIDS.
  • Therefore, routine HIV screening of all malignant lymphoma patients at MNH is necessary to enable comprehensive ARL diagnosis and formulation of preventive and therapeutic protocols.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology. Burkitt Lymphoma / virology. Child. Child, Preschool. Female. HIV Seropositivity. Hodgkin Disease / epidemiology. Hodgkin Disease / etiology. Hodgkin Disease / virology. Humans. Immunohistochemistry. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Tanzania / epidemiology


13. Deffenbacher KE, Iqbal J, Liu Z, Fu K, Chan WC: Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression. J Acquir Immune Defic Syndr; 2010 May 1;54(1):18-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression.
  • HIV-infected individuals have a significantly increased risk of developing an aggressive B-cell Non-Hodgkin Lymphoma relative to HIV(-) persons.
  • Due to their aggressive nature, AIDS-related lymphomas (ARL) can also be more difficult to classify.
  • Genetic abnormalities are known to play a significant role in HIV(-) lymphomagenesis.
  • Gene expression-based predictors robustly classified the B-ARL cases, distinguishing Burkitt lymphoma and diffuse large B-cell lymphoma, and identifying activated B-cell like and germinal center B-cell like molecular subtypes of diffuse large B-cell lymphoma.
  • These data demonstrate the ability to molecularly classify B-ARL lymphomas by gene expression and identified DNA copy number alterations targeted in B-ARL.
  • [MeSH-major] Chromosome Aberrations. Gene Dosage. Gene Expression. HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adult. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Comparative Genomic Hybridization. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216076.001).
  • [ISSN] 1944-7884
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / 5U01/CA114778-02S1; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / U01/CA84967
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Gotoh M, Kitahara T, Iguchi T, Izumi M, Mukai K, Ohyashiki K: [HIV-related multiple non-Hodgkin lymphomas]. Rinsho Ketsueki; 2008 Nov;49(11):1552-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HIV-related multiple non-Hodgkin lymphomas].
  • He was HIV-positive, and had gastric diffuse large B-cell lymphoma and renal T-cell anaplastic large cell lymphoma (T-ALCL).
  • We diagnosed double lymphomas related to AIDS.
  • The patient received anti-retroviral therapy, and started the CHOP regimen for the double lymphomas, resulting in transient improvement.
  • Biopsy specimen demonstrated null cell ALCL, and this patient demonstrated multiple lymphomas.
  • This case suggested that cancer generation was promoted by low immunity, although it is known that ambivalent tumors such as non-Hodgkin lymphomas can occur frequently.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, T-Cell / diagnosis. Neoplasms, Multiple Primary. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047787.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


15. Lim ST, Levine AM: Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma. CA Cancer J Clin; 2005 Jul-Aug;55(4):229-41; 260-1, 264
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.
  • Human immunodeficiency virus-infected patients are at an increased risk for developing both Hodgkin and non-Hodgkin lymphoma when compared with the general population.
  • With the remarkable decrease in the incidence of opportunistic infections since the availability of highly active antiretroviral therapy (HAART), acquired immune deficiency syndrome-related lymphoma (ARL) is now the second most common cancer associated with human immunodeficiency virus after Kaposi sarcoma.
  • Over the last few years, advances in our understanding of the molecular biology of this heterogeneous group of lymphomas have led to the adoption of new classification systems.
  • Apart from the contribution of HAART, this improvement in prognosis can also be attributed to new initiatives in treatment of these patients, such as the use of effective infusional regimens, the feasibility of high-dose therapy with peripheral stem cell rescue for relapsed or refractory disease, and better supportive care.
  • Nonetheless, several controversial issues persist, including the optimal timing of HAART with combination chemotherapy, the role of rituximab when incorporated into treatment regimens, and the optimal therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / physiopathology
  • [MeSH-minor] AIDS-Related Opportunistic Infections. Drug Administration Schedule. Humans. Incidence. Peripheral Blood Stem Cell Transplantation. Prevalence. Prognosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020424.001).
  • [ISSN] 0007-9235
  • [Journal-full-title] CA: a cancer journal for clinicians
  • [ISO-abbreviation] CA Cancer J Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


16. Epeldegui M, Widney DP, Martínez-Maza O: Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol; 2006 Sep;18(5):444-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions.
  • PURPOSE OF REVIEW: We discuss recently published studies that elucidate the pathogenesis of AIDS-associated lymphoma.
  • RECENT FINDINGS: Several recent reports have provided valuable new information on the role of gamma-herpesviruses in the pathogenesis of AIDS-associated lymphoma.
  • In addition to this, significant new information has become available on how B cell activation-associated DNA-modifying events, involving activation-induced cytidine deaminase and DNA polymerase-eta, contribute to the molecular lesions that result in AIDS-associated lymphoma.
  • In particular, new evidence that oncogenic viruses can directly induce activation-induced cytidine deaminase expression and oncogene mutation in human B cells is of central relevance to better understanding the pathogenesis of AIDS-associated lymphoma.
  • SUMMARY: New information provides insights into the contributions of immune dysfunction and oncogenic virus infection to pathogenesis of AIDS-associated lymphoma, and may lead to new potential targets for therapeutic intervention in these cancers.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / virology. Lymphoma, B-Cell / genetics. Oncogenic Viruses / pathogenicity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894291.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI35040; United States / NCI NIH HHS / CA / CA57152; United States / NCI NIH HHS / CA / CA70080; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.7 / DNA-Directed DNA Polymerase; EC 2.7.7.7 / Rad30 protein; EC 3.5.4.5 / Cytidine Deaminase
  • [Number-of-references] 28
  •  go-up   go-down


17. Yamanaka K, Fuhlbrigge RC, Mizutani H, Kupper TS: Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell lymphoma. Arch Dermatol Res; 2010 Aug;302(6):453-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell lymphoma.
  • In advanced stages, cutaneous T cell lymphomas (CTCL) are associated with increased mortality from infections and also increased susceptibility to skin malignancies.

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Dermatol. 2003 Feb;42(2):116-22 [12708999.001]
  • [Cites] AIDS. 2003 May 2;17(7):947-54 [12700443.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4059-66 [12829591.001]
  • [Cites] N Engl J Med. 2004 Feb 19;350(8):757-66 [14973217.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):701-5 [15097953.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):749-59 [15365096.001]
  • [Cites] J Am Acad Dermatol. 1981 Feb;4(2):176-80 [7217388.001]
  • [Cites] J Dermatol. 1990 Aug;17(8):477-81 [2229651.001]
  • [Cites] JAMA. 1992 Mar 11;267(10):1354-8 [1740857.001]
  • [Cites] J Invest Dermatol. 1992 Jul;99(1):90-4 [1607682.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1383-9 [8695857.001]
  • [Cites] Arch Dermatol Res. 1996 Dec;289(1):9-13 [9017129.001]
  • [Cites] Pediatr Res. 1998 Mar;43(3):396-402 [9505280.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1640-7 [15514008.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):798-812 [15841167.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5748-55 [16115912.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):376-82 [16428475.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2440-5 [16322477.001]
  • [Cites] Infection. 2008 Mar;36(2):120-9 [18379725.001]
  • [Cites] Clin Lymphoma Myeloma. 2008 Apr;8(2):100-5 [18501103.001]
  • [Cites] Semin Immunol. 2008 Jun;20(3):196-203 [18757210.001]
  • [Cites] J Am Acad Dermatol. 2008 Dec;59(6):949-52 [18835065.001]
  • [Cites] Blood. 2000 Jan 1;95(1):352-9 [10607724.001]
  • [Cites] Nat Biotechnol. 2000 Jul;18(7):729-34 [10888839.001]
  • [Cites] Nat Immunol. 2000 Aug;1(2):132-7 [11248805.001]
  • [Cites] J Am Acad Dermatol. 2001 Aug;45(2):208-16 [11464181.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1116-21 [11493459.001]
  • [Cites] Hum Immunol. 2002 Jan;63(1):51-60 [11916170.001]
  • [Cites] Clin Exp Immunol. 2003 Apr;132(1):105-12 [12653844.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):909-13 [12873887.001]
  • (PMID = 20111968.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI041707-12; United States / NCI NIH HHS / CA / P50 CA093683-07; United States / NIAID NIH HHS / AI / R01 AI041707-12; United States / NCI NIH HHS / CA / P50 CA093683; United States / NIAID NIH HHS / AI / R01 AI041707
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Receptors, Antigen, T-Cell; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  • [Other-IDs] NLM/ NIHMS190229; NLM/ PMC2892560
  •  go-up   go-down


18. Tanaka PY, Calore EE: P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients. Pathol Res Pract; 2007;203(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients.
  • It still needs to be clarified whether P-gp expression has a significant impact on non-Hodgkin's lymphoma treatment response, but a poor outcome has been reported in patients with positive P-gp expression.
  • AIDS-related lymphomas have aggressive behavior, and although a complete response could be achieved, relapse is not uncommon.
  • In an attempt to determine a possible relationship between MDR and poor outcome in this population, histologic samples obtained from 45 non-Hodgkin's lymphoma HIV-infected patients without previous cytotoxic therapy were submitted to immunohistochemical analysis using monoclonal antibody C494 specific for the MDR-1 isoform of P-gp.
  • In patients having achieved complete remission, the median disease-free survival (DFS) was not reached; the mean DFS was 57.2 months with DFS rates of 72.9% in three years.
  • Our results show that P-gp is expressed before treatment of non-Hodgkin's lymphoma of HIV patients, and is related to poor response to treatment and overall survival.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Lymphoma, AIDS-Related / metabolism. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / mortality. Biomarkers, Tumor / metabolism. Cell Count. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathol Res Pract. 2007;203(10):763
  • (PMID = 17157997.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


19. Martini M, Capello D, Serraino D, Navarra A, Pierconti F, Cenci T, Gaidano G, Larocca LM: Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas. J Infect; 2007 Mar;54(3):298-306
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas.
  • OBJECTIVE: The aim of this study was to determine the occurrence of polymorphic variants of EBV BamHI fragment Z (BZLF1) promoter zone Zp in tumor and non-tumor-associated EBV.
  • We characterized the Zp region in type A and type B EBV, infecting AIDS-related non-Hodgkin's lymphomas (AIDS-NHL) and non-malignant lymphoid tissues derived from HIV-positive patients and from healthy individuals.
  • METHODS: The Zp region was directly sequenced in 133 EBV-positive DNA samples: 63 AIDS-NHL (32 systemic AIDS-NHL and 31 AIDS-primary central nervous system lymphoma [AIDS-PCNSL]), 30 lymphoid tissues derived from HIV-positive individuals and 40 lymphoid samples derived from healthy individuals.
  • Zp-V3 was significantly associated with AIDS-PCNSL (P<0.001) and with systemic AIDS-NHL (P=0.007), in particular with AIDS-related immunoblastic lymphoma (P<0.001).
  • Moreover, in malignant samples, this variant was also significantly associated with type B EBV (P<0.001).
  • Finally, the new identified Zp-PV variant was isolated in 7 AIDS-PCNSL.
  • CONCLUSIONS: The frequency of polymorphisms in the regulatory zone of BZLF1 is different between malignant and non-malignant samples in AIDS patients and may identify EBV subtypes with different transforming activities, including those associated to the pathogenesis of B cell lymphoma.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / virology. DNA-Binding Proteins / genetics. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / genetics. Lymphoma / virology. Promoter Regions, Genetic. Trans-Activators / genetics. Viral Proteins / genetics
  • [MeSH-minor] DNA, Viral / genetics. Humans. Lymphoid Tissue / virology. Lymphoma, AIDS-Related / virology. Polymorphism, Genetic. Sequence Analysis, DNA. Statistics as Topic

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784778.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BZLF1 protein, Herpesvirus 4, Human; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / Trans-Activators; 0 / Viral Proteins
  •  go-up   go-down


20. Subirá D, Górgolas M, Castañón S, Serrano C, Román A, Rivas F, Tomás JF: Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients. HIV Med; 2005 Jan;6(1):21-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.
  • BACKGROUND: Neurological disorders are common in HIV-infected patients.
  • Central nervous system (CNS) lymphoma should always be considered because it is an important cause of morbidity and mortality.
  • OBJECTIVES: To investigate the clinical utility of flow cytometry immunophenotyping (FCI) in diagnosing or discarding leptomeningeal involvement in HIV-infected patients and to compare its sensitivity with that of conventional cytological methods.
  • METHODS: Fifty-six cerebrospinal fluid (CSF) samples from 29 HIV-infected patients were independently evaluated by flow cytometry and cytology.
  • RESULTS: FCI and cytology gave concordant results for 48 of the 56 CSF samples studied: 37 were negative for malignancy and 11 had evidence of CNS lymphoma.
  • This advantage suggests that, in case of negative flow cytometry results, disorders other than non-Hodgkin's lymphoma should be strongly considered.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Burkitt Lymphoma / cerebrospinal fluid. Burkitt Lymphoma / diagnosis. Diagnosis, Differential. Female. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670248.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Nyagol J, De Falco G, Lazzi S, Luzzi A, Cerino G, Shaheen S, Palummo N, Bellan C, Spina D, Leoncini L: HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas. J Hematop; 2008 Jul;1(1):3-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas.
  • In some subtypes of non-Hodgkin's lymphomas, higher local vascular endothelial growth factor (VEGF) expression correlates with increased microvessel density.
  • Several studies have indicated that VEGF receptors are also targeted by Tat protein from the HIV-1-infected cells.
  • We evaluated the role of HIV-1 Tat in regulating the level of VEGF expression and microvessel density in the AIDS-related diffuse large B-cell (DLBCL) and Burkitt lymphomas (BL).
  • Reduced VEGF protein expression in primary HIV-1 positive BL and DLBCL, compared to the negative cases, supported the findings of promoter downregulation from the cell lines.
  • Microvascular density assessed by CD34 expression was, however, higher in HIV-1 positive than in HIV-1 negative tumors.
  • Thus, targeting Tat protein itself and stabilizing transient silencing of VEGF expression or use of monoclonal antibodies against their receptors in the AIDS-associated tumors will open a window for future explorable pathways in the management of angiogenic phenotypes in the AIDS-associated non-Hodgkin's lymphomas.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1996 Dec;2(12):1371-5 [8946838.001]
  • [Cites] Oncogene. 2000 Jan 20;19(3):373-9 [10656684.001]
  • [Cites] Oncogene. 1996 Jan 18;12(2):289-97 [8570206.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):66-70 [7596436.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):2014-21 [17917969.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):223-30 [17595666.001]
  • [Cites] Exp Cell Res. 2007 May 1;313(8):1561-74 [17382929.001]
  • [Cites] Am J Pathol. 2007 Apr;170(4):1362-9 [17392174.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4647-52 [17360578.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 13;355(3):693-9 [17320821.001]
  • [Cites] Nat Struct Mol Biol. 2007 Mar;14(3):249-50 [17293873.001]
  • [Cites] J Cell Biochem. 2007 Feb 15;100(3):727-37 [17115409.001]
  • [Cites] Curr Med Chem. 2006;13(16):1845-57 [16842197.001]
  • [Cites] FEBS J. 2005 Nov;272(22):5723-41 [16279938.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(4):241-3 [15704651.001]
  • [Cites] Biochem Pharmacol. 2004 Dec 15;68(12):2359-66 [15548382.001]
  • [Cites] Circulation. 1997 Dec 2;96(11):4083-94 [9403634.001]
  • [Cites] J Biol Chem. 1998 Nov 20;273(47):31119-24 [9813014.001]
  • [Cites] Science. 1998 Dec 4;282(5395):1837-9 [9874635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6 [9520456.001]
  • [Cites] J Clin Pathol. 1997 Jun;50(6):481-4 [9378813.001]
  • [Cites] Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5 [7542074.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]
  • [Cites] Nature. 1994 Oct 20;371(6499):674-80 [7935812.001]
  • [Cites] Arch Orthop Trauma Surg. 2003 Nov;123(9):475-80 [12750926.001]
  • [Cites] Angiogenesis. 2002;5(3):141-51 [12831055.001]
  • [Cites] Cell Prolif. 2003 Jun;36(3):131-49 [12814430.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):115-28 [12769789.001]
  • [Cites] J Rheumatol. 2003 Feb;30(2):260-8 [12563678.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • [Cites] Hum Pathol. 2002 Jul;33(7):723-31 [12196924.001]
  • [Cites] Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44 [11965229.001]
  • [Cites] Clin Microbiol Rev. 2002 Apr;15(2):310-26 [11932235.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):838-45 [11764072.001]
  • [Cites] Biochem J. 2001 Feb 1;353(Pt 3):569-78 [11171054.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):462-8 [11212232.001]
  • [Cites] Curr Opin Oncol. 2000 Sep;12(5):445-9 [10975552.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):267-71 [10873597.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:3-10 [10804084.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1065-74 [8644848.001]
  • (PMID = 19669199.001).
  • [ISSN] 1868-9256
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2712328
  •  go-up   go-down


22. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF: HIV-associated lymphomas and gamma-herpesviruses. Blood; 2009 Feb 5;113(6):1213-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated lymphomas and gamma-herpesviruses.
  • Among the most common HIV-associated lymphomas are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with immunoblastic-plasmacytoid differentiation (also involving the central nervous system).
  • Lymphomas occurring specifically in HIV-positive patients include primary effusion lymphoma (PEL) and its solid variants, plasmablastic lymphoma of the oral cavity type and large B-cell lymphoma arising in Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease.
  • These lymphomas together with BL and DLBCL with immunoblastic-plasmacytoid differentiation frequently carry EBV infection and display a phenotype related to plasma cells.
  • EBV infection occurs at different rates in different lymphoma types, whereas KSHV is specifically associated with PEL, which usually occurs in the setting of profound immunosuppression.
  • The current knowledge about HIV-associated lymphomas can be summarized in the following key points:.
  • (1) lymphomas specifically occurring in patients with HIV infection are closely linked to other viral diseases;.
  • (2) AIDS lymphomas fall in a spectrum of B-cell differentiation where those associated with EBV or KSHV commonly exhibit plasmablastic differentiation; and (3) prognosis for patients with lymphomas and concomitant HIV infection could be improved using better combined chemotherapy protocols incorporating anticancer treatments and antiretroviral drugs.
  • [MeSH-major] Gammaherpesvirinae / pathogenicity. HIV-1 / pathogenicity. Herpesviridae Infections / virology. Lymphoma, AIDS-Related / virology


23. Fakhari FD, Jeong JH, Kanan Y, Dittmer DP: The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest; 2006 Mar;116(3):735-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma.
  • Kaposi sarcoma-associated herpesvirus (KSHV) is a human lymphotropic herpesvirus.
  • It is implicated in B cell neoplasias such as primary effusion lymphoma and multicentric Castleman disease in AIDS patients.
  • The KSHV latency-associated nuclear antigen (LANA) is consistently expressed in all KSHV-associated tumor cells and was shown to bind the tumor suppressor proteins p53 and pRb.
  • We also observed lymphomas, implying that LANA can activate B cells and provide the first step toward lymphomagenesis.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2003 Jan;3(1):23-36 [12559173.001]
  • [Cites] J Virol. 2002 Nov;76(21):11024-32 [12368345.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] J Virol. 2003 Jun;77(11):6474-81 [12743304.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] J Clin Invest. 2004 Jan;113(1):124-36 [14702116.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):581-9 [14744772.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2145-8 [15150582.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(12):4781-4 [2352948.001]
  • [Cites] EMBO J. 1992 May;11(5):1891-9 [1582417.001]
  • [Cites] Eur J Immunol. 1992 Nov;22(11):3001-11 [1425924.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] J Exp Med. 1996 Jul 1;184(1):283-8 [8691144.001]
  • [Cites] N Engl J Med. 1998 Apr 2;338(14):948-54 [9521982.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3862-74 [15525642.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2626-35 [15805259.001]
  • [Cites] Leukemia. 2005 May;19(5):851-5 [15744337.001]
  • [Cites] Cancer Cell. 2005 May;7(5):445-55 [15894265.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5925-34 [15994971.001]
  • [Cites] Virology. 1999 Nov 25;264(2):254-64 [10562490.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1857-68 [10601360.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):77-85 [10658913.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):1961-70 [10657646.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] J Virol. 2001 Jan;75(1):458-68 [11119614.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] J Virol. 2001 Feb;75(4):1798-807 [11160678.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2130-6 [11264181.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4119-24 [11274437.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22971-8 [11313352.001]
  • [Cites] J Virol. 2001 Sep;75(17):7882-92 [11483733.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • [Cites] Blood. 2002 Jul 1;100(1):246-58 [12070034.001]
  • [Cites] Clin Microbiol Rev. 2002 Jul;15(3):439-64 [12097251.001]
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • (PMID = 16498502.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / CA109232
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / latency-associated nuclear antigen
  • [Other-IDs] NLM/ PMC1378187
  •  go-up   go-down


24. Miyake A, Dewan MZ, Ishida T, Watanabe M, Honda M, Sata T, Yamamoto N, Umezawa K, Watanabe T, Horie R: Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. Microbes Infect; 2008 Jun;10(7):748-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV) causes EBV-associated lymphoproliferative diseases in patients with profound immune suppression.
  • Most of these diseases are life-threatening and the prognosis of AIDS-associated lymphomas is extremely unfavorable.
  • We investigated the possibility of nuclear factor kappa B (NF-kappaB) inhibition by dehydroxymethylepoxyquinomicin (DHMEQ) for the treatment and prevention of EBV-associated lymphoproliferative diseases.
  • These results suggest that NF-kappaB is a molecular target for the treatment and prevention of EBV-associated lymphoproliferative diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538617.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cyclohexanones; 0 / Immunologic Factors; 0 / NF-kappa B; 0 / dehydroxymethylepoxyquinomicin
  •  go-up   go-down


25. Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Fachiroh J, Paramita DK, Tan IB, Haryana SM, Middeldorp JM: Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol; 2005 Jul;43(7):3066-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasopharyngeal carcinoma (NPC) is a prevalent malignancy in Southeast Asia and is strongly associated with Epstein-Barr virus (EBV).
  • The presence of circulating tumor cells was assessed by amplification of BamHI-A rightward frame 1 (BARF1) mRNA, a viral oncogene abundantly expressed in EBV-carrying carcinomas but virtually absent from EBV-associated lymphomas.

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5452-5 [10554016.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1046-51 [10741733.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2745-8 [10825150.001]
  • [Cites] J Virol. 2000 Oct;74(19):9078-82 [10982353.001]
  • [Cites] Klin Padiatr. 2000 Jul-Aug;212(4):206-10 [10994552.001]
  • [Cites] J Gen Virol. 2000 Oct;81(Pt 10):2417-23 [10993929.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5584-8 [11034107.001]
  • [Cites] J Virol. 2000 Nov;74(22):10681-9 [11044112.001]
  • [Cites] Protein Expr Purif. 2000 Nov;20(2):324-33 [11049756.001]
  • [Cites] J Virol Methods. 2000 Nov;90(2):193-204 [11064119.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):248-54 [11091848.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4055-63 [11110673.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):1-10 [11227065.001]
  • [Cites] J Mol Diagn. 2000 Nov;2(4):191-201 [11232109.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1165-71 [11222357.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1211-6 [11283029.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2607-15 [11352952.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):433-7 [11839660.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):723-9 [11857305.001]
  • [Cites] Mol Biotechnol. 2002 Feb;20(2):163-79 [11876473.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):75-82 [11905817.001]
  • [Cites] AIDS. 2002 May 3;16(7):993-1001 [11953465.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):831-40 [12153173.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2612-9 [12171892.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):3986-92 [12409363.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):4105-13 [12409382.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9 [12419787.001]
  • [Cites] Semin Cancer Biol. 2002 Dec;12(6):431-41 [12450729.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Jan;45(1):1-36 [12482570.001]
  • [Cites] J Clin Virol. 2003 Oct;28(2):155-64 [12957185.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3254-9 [12960110.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3431-4 [12960133.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5245-9 [14605174.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):239-44 [14688409.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1162-70 [15022282.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1429-37 [15042677.001]
  • [Cites] Cancer Sci. 2004 Jun;95(6):508-13 [15182432.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]
  • [Cites] J Infect Dis. 2004 Jul 1;190(1):53-62 [15195243.001]
  • [Cites] Oncogene. 2004 Jun 17;23(28):4938-44 [15064715.001]
  • [Cites] Methods Mol Biol. 2005;292:15-26 [15507698.001]
  • [Cites] Int J Cancer. 1976 Jan 15;17(1):1-7 [175020.001]
  • [Cites] Int J Cancer. 1977 Nov 15;20(5):655-62 [200568.001]
  • [Cites] J Gen Virol. 1985 Sep;66 ( Pt 9):1931-40 [2993484.001]
  • [Cites] J Virol. 1987 Dec;61(12):3870-8 [2824821.001]
  • [Cites] Nature. 1989 May 18;339(6221):237-8 [2716852.001]
  • [Cites] EMBO J. 1989 Oct;8(10):2897-903 [2555151.001]
  • [Cites] J Clin Microbiol. 1990 Mar;28(3):495-503 [1691208.001]
  • [Cites] Oncogene. 1993 Jun;8(6):1575-83 [8389032.001]
  • [Cites] J Clin Microbiol. 1997 Jun;35(6):1612-5 [9163497.001]
  • [Cites] Oncogene. 1997 Jun 26;14(25):3073-81 [9223671.001]
  • [Cites] J Virol Methods. 1997 Sep;67(2):199-207 [9300385.001]
  • [Cites] Clin Chem. 1997 Oct;43(10):1843-9 [9342002.001]
  • [Cites] Clin Cancer Res. 1998 Mar;4(3):665-9 [9533535.001]
  • [Cites] J Med Virol. 1998 Jul;55(3):227-33 [9624611.001]
  • [Cites] J Virol Methods. 1998 Jun;72(2):175-84 [9694325.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] J Clin Microbiol. 1998 Nov;36(11):3164-9 [9774558.001]
  • [Cites] J Clin Microbiol. 1999 Sep;37(9):2852-7 [10449464.001]
  • [Cites] Mol Pathol. 1999 Apr;52(2):97-103 [10474689.001]
  • [Cites] Transpl Infect Dis. 2001 Jun;3(2):79-87 [11395973.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1033-8 [12631603.001]
  • [Cites] Cell Death Differ. 2003 Jan;10(1):108-16 [12655299.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2028-32 [12727814.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):706-9 [12740922.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):288-91 [12872347.001]
  • (PMID = 16002393.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC1169169
  •  go-up   go-down


26. Gujral S, Gandhi JS, Valsangkar S, Shet TM, Epari S, Subramanian PG: Study of the morphological patterns and association of Epstein-Barr virus and human herpes virus 8 in acquired immunodeficiency deficiency syndrome-related reactive lymphadenopathy. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):723-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of the morphological patterns and association of Epstein-Barr virus and human herpes virus 8 in acquired immunodeficiency deficiency syndrome-related reactive lymphadenopathy.
  • AIMS: Study of the morphological patterns of acquired immunodeficiency syndrome (AIDS)-related lymphadenopathy.
  • SETTINGS AND DESIGN: We retrospectively selected cases of AIDS-related benign lymphadenopathy.
  • Cases with lymphomas, frank granulomas and necrosis were excluded.
  • We analyzed different morphological patterns and correlated these with immunophenotypic markers along with viral markers human herpesvirus 8-latency-associated nuclear antigen (HHV8-LANA), and Epstein-Barr virus-encoded ribonucleic acid (EBER) studies via in situ hybridization (EBER-ISH).
  • MATERIALS AND METHODS: We present the morphological patterns of 13 cases of human immunodeficiency virus (HIV)-reactive lymph nodes and their clinical, hematological, biochemical and radiological parameters with special emphasis on the presence or absence of viral markers, including HHV8 and EBV.
  • Two cases of multicentric Castleman's disease expressed EBER; however, they did not express HHV8.
  • CONCLUSION: The wide spectrum of histological changes in HIV-associated lymphadenopathy requires recognition.
  • The histological changes can mimic those of other infective lymphadenitis, follicular lymphoma, Castleman's disease, progressive transformation of germinal center, Hodgkin's disease and spindle cell neoplasms.
  • [MeSH-major] AIDS-Related Opportunistic Infections / pathology. Epstein-Barr Virus Infections / pathology. HIV Infections / complications. Herpesviridae Infections / pathology. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Lymphatic Diseases / pathology


27. Epeldegui M, Vendrame E, Martínez-Maza O: HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. Immunol Res; 2010 Dec;48(1-3):72-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.
  • HIV infection is associated with a much higher risk for the development of non-Hodgkin lymphoma (AIDS-NHL).
  • The principal causes of lymphomagenesis in HIV-infected individuals are thought to be the loss of immune function seen in HIV infection, which results in the loss of immunoregulation of Epstein-Barr virus-infected B cells, as well as HIV infection-associated immune dysregulation, including chronic B-cell activation.
  • In this review, we discuss recent reports that further support the importance of these factors, and we highlight emerging evidence of different mechanisms that potentially drive lymphomagenesis in HIV-infected individuals.
  • [MeSH-major] AIDS-Related Opportunistic Infections / immunology. Acquired Immunodeficiency Syndrome / immunology. B-Lymphocytes / immunology. Epstein-Barr Virus Infections / immunology. HIV / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology


28. Shackelford J, Pagano JS: Role of the ubiquitin system and tumor viruses in AIDS-related cancer. BMC Biochem; 2007;8 Suppl 1:S8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the ubiquitin system and tumor viruses in AIDS-related cancer.
  • This review focuses on examples of human oncogenic viruses that manipulate the ubiquitin system in a subset of viral malignancies; those associated with AIDS.
  • The viruses include Kaposi's sarcoma herpesvirus, Epstein-Barr virus and human papilloma virus, which are causally linked to Kaposi's sarcoma, certain B-cell lymphomas and cervical cancer, respectively.
  • Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] Cell Cycle. 2004 Nov;3(11):1345-7 [15492505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13057-62 [11087859.001]
  • [Cites] Acta Virol. 2000 Jun-Aug;44(3):211-26 [11155368.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1218-23 [11158620.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1227-35 [11423255.001]
  • [Cites] J Virol. 2001 Aug;75(16):7583-91 [11462030.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4740-9 [11498796.001]
  • [Cites] Chem Biol. 2001 Aug;8(8):739-58 [11514224.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):637-46 [11710679.001]
  • [Cites] J Cell Biol. 2001 Dec 24;155(7):1265-73 [11756476.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6124-30 [11751860.001]
  • [Cites] Nat Med. 2002 Apr;8(4):338-40 [11927937.001]
  • [Cites] EMBO J. 2002 May 15;21(10):2418-29 [12006494.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] Oral Dis. 2002;8 Suppl 2:161-8 [12164651.001]
  • [Cites] Curr Top Microbiol Immunol. 2002;269:23-36 [12224511.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):15-24 [12406543.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] Semin Cancer Biol. 2002 Dec;12(6):431-41 [12450729.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):59-67 [12507557.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):69-76 [12507558.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):159-69 [12584163.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):307-12 [12619117.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Med Sci (Paris). 2003 Jan;19(1):100-6 [12836198.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):697-702, v-vi [12852651.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Isr Med Assoc J. 2004 Jul;6(7):420-4 [15274534.001]
  • [Cites] Trends Immunol. 2004 Aug;25(8):422-6 [15275641.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:717-46 [15338771.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):453-71 [15489139.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Science. 1989 Feb 17;243(4893):934-7 [2537532.001]
  • [Cites] EMBO J. 1989 Dec 20;8(13):4099-105 [2556261.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):630-9 [15659509.001]
  • [Cites] Annu Rev Med. 2005;56:29-44 [15660500.001]
  • [Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]
  • [Cites] Viral Immunol. 2004;17(4):473-80 [15671745.001]
  • [Cites] Cleve Clin J Med. 2005 Jan;72(1):73-8 [15691060.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Mar;53(3):253-65 [15718150.001]
  • [Cites] Curr Med Chem. 2005;12(3):357-74 [15723624.001]
  • [Cites] Expert Opin Emerg Drugs. 2005 Feb;10(1):5-19 [15757400.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:465-76 [15822185.001]
  • [Cites] J Virol. 2005 May;79(9):5705-12 [15827185.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):222-8 [15842046.001]
  • [Cites] Anticancer Drugs. 2005 Jun;16(5):475-81 [15846112.001]
  • [Cites] Cell Cycle. 2005 Feb;4(2):290-6 [15655370.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2005 Feb;100(1):1-12 [15867955.001]
  • [Cites] AIDS Rev. 2005 Jan-Mar;7(1):56-61 [15875661.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):412-26 [15967835.001]
  • [Cites] Science. 2005 Jul 1;309(5731):127-30 [15994556.001]
  • [Cites] J Antimicrob Chemother. 2005 Aug;56(2):277-81 [16006448.001]
  • [Cites] EMBO J. 2006 Apr 19;25(8):1635-45 [16601694.001]
  • [Cites] Adv Dent Res. 2006;19(1):99-105 [16672559.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1495-502 [16679162.001]
  • [Cites] Curr Mol Med. 2006 May;6(3):291-308 [16712476.001]
  • [Cites] Front Biosci. 2006;11:2672-713 [16720343.001]
  • [Cites] Cancer Treat Rev. 2006 Oct;32(6):445-55 [16860939.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9870-7 [17047048.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(8):2910-8 [17296724.001]
  • [Cites] Adv Cancer Res. 2000;78:1-29 [10547667.001]
  • [Cites] Oncogene. 1999 Dec 13;18(53):7690-700 [10618709.001]
  • [Cites] Virology. 2000 Mar 1;268(1):178-91 [10683340.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):387-95 [10712885.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):717-45 [12852653.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3A):2133-8 [12894587.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5122-30 [12910249.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]
  • [Cites] Ann Med. 2003;35(6):404-12 [14572164.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15572-6 [14663138.001]
  • [Cites] AIDS Rev. 2003 Oct-Dec;5(4):222-9 [15012001.001]
  • [Cites] Oncogene. 2004 Mar 15;23(11):2107-15 [15021898.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):349-60 [15122206.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5089-93 [15169876.001]
  • [Cites] Curr Protein Pept Sci. 2004 Jun;5(3):153-61 [15180520.001]
  • [Cites] Oncologist. 2005 Aug;10(7):528-38 [16079320.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):155-67 [15979320.001]
  • [Cites] Antivir Ther. 2005;10(6):745-51 [16218174.001]
  • [Cites] Essays Biochem. 2005;41:139-56 [16250903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18431-6 [16344472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18562-6 [16352731.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] Ann Pharm Fr. 2005 Sep;63(5):343-9 [16385784.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:328-43 [16387699.001]
  • [Cites] Annu Rev Med. 2006;57:33-47 [16409135.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Feb;15(2):117-30 [16433592.001]
  • [Cites] Yonsei Med J. 2006 Feb 28;47(1):1-14 [16502480.001]
  • [Cites] Cancer Gene Ther. 2006 May;13(5):445-50 [16341140.001]
  • [Cites] Curr Med Chem. 2006;13(7):745-54 [16611064.001]
  • [Cites] Nihon Rinsho. 2006 Mar;64 Suppl 3:635-8 [16615550.001]
  • [Cites] Int J Oncol. 2000 May;16(5):853-70 [10762621.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] Bioessays. 2000 May;22(5):442-51 [10797484.001]
  • [Cites] Clin Lab Med. 2000 Jun;20(2):383-406 [10863646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Adv Pharmacol. 2000;49:479-514 [11013772.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(22):8526-35 [11046148.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1129-36 [2175676.001]
  • [Cites] Hum Cell. 1992 Mar;5(1):25-41 [1329931.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Princess Takamatsu Symp. 1991;22:239-48 [1668886.001]
  • [Cites] Int J Cancer. 1993 Sep 9;55(2):208-12 [8370617.001]
  • [Cites] Hosp Pract (1995). 1996 Sep 15;31(9):41-8, 53-5, 59-60 [8814120.001]
  • [Cites] Mol Med Today. 1997 Jun;3(6):246-53 [9211415.001]
  • [Cites] Semin Cancer Biol. 1996 Dec;7(6):317-26 [9284524.001]
  • [Cites] J Biol Chem. 1997 Nov 28;272(48):30135-40 [9374493.001]
  • [Cites] FEBS Lett. 1997 Dec 22;420(1):25-7 [9450543.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6439-45 [9497376.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Nature. 1998 Aug 6;394(6693):588-92 [9707121.001]
  • [Cites] Trends Microbiol. 1998 Jul;6(7):276-82 [9717216.001]
  • [Cites] Oncogene. 1998 Dec 10;17(23):2943-54 [9881696.001]
  • [Cites] Front Biosci. 1999 May 15;4:D468-75 [10331991.001]
  • (PMID = 18047745.001).
  • [ISSN] 1471-2091
  • [Journal-full-title] BMC biochemistry
  • [ISO-abbreviation] BMC Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ubiquitin
  • [Number-of-references] 119
  • [Other-IDs] NLM/ PMC2106372
  •  go-up   go-down


29. Kelemen K, Cao W, Peterson LC, Evens AM, Variakojis D: Primary mediastinal large B-cell lymphoma in HIV: report of two cases. J Hematop; 2009 Mar;2(1):45-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma in HIV: report of two cases.
  • Primary mediastinal large B cell lymphoma (PMLBCL) is a subtype of diffuse large B cell lymphoma arising in the mediastinum with distinctive clinical and morphological features.
  • Though diffuse large B cell lymphoma is one of the most common non-Hodgkin lymphoma associated with AIDS, there are no data available regarding the association of HIV and PMLBCL.
  • We report here two cases of PMLBCL arising in AIDS patients.
  • One of the two patients, a 25-year-old woman who had localized disease and evidence of Epstein-Barr virus in lymphoma cells, did not respond to chemotherapy and died of disease progression 5 months after diagnosis.
  • The second patient, a 38-year-old male with disseminated disease, responded to therapy and is disease-free after 9 months of follow-up.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Pathol Jpn. 1993 Jan-Feb;43(1-2):44-54 [8465656.001]
  • [Cites] J Pathol. 1992 Aug;167(4):381-4 [1328576.001]
  • [Cites] Blood. 1991 Aug 1;78(3):780-8 [1713514.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • [Cites] Blood. 2007 Aug 1;110(3):972-8 [17400912.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Am J Med Sci. 2005 Mar;329(3):136-8 [15767818.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):1135-48 [8880201.001]
  • [Cites] Br J Haematol. 1995 Jun;90(2):235-43 [7794745.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • (PMID = 19669223.001).
  • [ISSN] 1868-9256
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2713493
  •  go-up   go-down


30. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA: Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol; 2006 Feb;54(2):189-206; quiz 207-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous malignancy and human immunodeficiency virus disease.
  • Certain skin cancers occur with increased frequency or altered course in patients infected with HIV.
  • Malignant melanoma and squamous cell carcinoma are examples of cutaneous malignancies that have a more aggressive course in patients with HIV.
  • The incidence of HIV-associated Kapsosi's sarcoma has markedly decreased since the advent of HIV antiretroviral therapy.
  • Cutaneous T-cell lymphoma (CTCL) is rare in this population.
  • Other types of cutaneous lymphoma and HIV-associated pseudo-CTCL are discussed.
  • LEARNING OBJECTIVE: At the completion of this learning activity, participants should be familiar with the unique epidemiology, clinical course, and management of cutaneous malignancy in patients infected with HIV.
  • [MeSH-major] HIV Infections / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Algorithms. Animals. Anti-Retroviral Agents / administration & dosage. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / isolation & purification. Humans. Immunity, Cellular. Immunohistochemistry. Lymphoma, Large-Cell, Anaplastic / epidemiology. Lymphoma, T-Cell, Cutaneous / epidemiology. Lymphoma, T-Cell, Cutaneous / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Melanoma / epidemiology. Melanoma / therapy. Papillomaviridae. Papillomavirus Infections / epidemiology. Risk Factors. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Seroepidemiologic Studies

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443048.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 274
  •  go-up   go-down


31. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, de Gruijl TD, Würdinger T, Middeldorp JM: Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A; 2010 Apr 6;107(14):6328-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These EBV-miRNAs are functional because internalization of exosomes by MoDC results in a dose-dependent, miRNA-mediated repression of confirmed EBV target genes, including CXCL11/ITAC, an immunoregulatory gene down-regulated in primary EBV-associated lymphomas.


32. Lawson JS, Heng B: Viruses and breast cancer. Cancers (Basel); 2010;2(2):752-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Viruses are the accepted cause of many important cancers including cancers of the cervix and anogenital area, the liver, some lymphomas, head and neck cancers and indirectly human immunodeficiency virus associated cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24281093.001).
  • [ISSN] 2072-6694
  • [Journal-full-title] Cancers
  • [ISO-abbreviation] Cancers (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3835103
  •  go-up   go-down


33. Shankar SK, Mahadevan A, Satishchandra P, Kumar RU, Yasha TC, Santosh V, Chandramuki A, Ravi V, Nath A: Neuropathology of HIV/AIDS with an overview of the Indian scene. Indian J Med Res; 2005 Apr;121(4):468-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuropathology of HIV/AIDS with an overview of the Indian scene.
  • Neurological manifestations of HIV infection and AIDS are being recognized with a frequency that parallels the increasing number of AIDS cases.
  • Next to sub-Saharan Africa, India has the second largest burden of HIV related pathology, essentially caused by HIV-1 clade C in both the geographic locales, in contrast to USA and Europe.
  • But the true prevalence of HIV related neuroinfections and pathology is not available due to inadequate medical facilities, social stigma and ignorance that lead to underdiagnosis.
  • Inspite of heavy burden of HIV/AIDS, HIV associated neoplasia is infrequent, including primary CNS lymphomas.
  • HIV encephalitis and HIV associated dementia are considered infrequent, though systematic studies have just been initiated in various centres.
  • Till now the AIDS cases in India were drug naive but a new cohort of cases following initiation of HAART therapy as a national policy is soon emerging, altering the biology and evolution of HIV/AIDS in India.
  • Lacunae in the epidemiology, diagnosis and study of biology of HIV/AIDS are outlined for future research.
  • [MeSH-major] Central Nervous System Neoplasms / complications. HIV Infections / physiopathology. Nervous System Diseases / complications

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15817957.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] India
  • [Number-of-references] 153
  •  go-up   go-down


34. Queiroga EM, Gualco G, Chioato L, Harrington WJ, Araujo I, Weiss LM, Bacchi CE: Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8. Am J Clin Pathol; 2008 Aug;130(2):186-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8.
  • Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma, composed of a monomorphic population of medium-sized B cells with a high proliferation rate and a consistent MYC translocation.
  • Epstein-Barr virus (EBV) has been associated with BL with different frequencies depending on the clinical variant.
  • Kaposi sarcoma-associated herpesvirus, or human herpesvirus 8 (HHV-8), infects a wide range of normal cells, having a well-established role in the pathogenesis of various neoplasms, including Kaposi sarcoma, primary effusion lymphoma, multicentric Castleman disease (MCD) and MCD-associated plasmablastic lymphoma.
  • In secondary immunodeficiencies, such as HIV-1 infection and organ transplantation, HHV-8 is considered an opportunistic pathogen linked to the development of lymphomas in patients with AIDS and HIV + patients.
  • We found no association of BL with HHV-8 in EBV + BL or in EBV-cases, including the HIV + BL group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Aug;19(8):1391-8 [15973450.001]
  • [Cites] J Exp Med. 2005 Aug 15;202(4):479-84 [16103407.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):834-7 [16136049.001]
  • [Cites] J Clin Pathol. 2005 Oct;58(10):1039-45 [16189148.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):123-7 [16330952.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):23-31 [16360412.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Acta Haematol. 2007;117(3):129-31 [17135725.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]
  • [Cites] Haematologica. 2005 Nov;90 Suppl:ECR35 [16266926.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1269-70 [10534180.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2130-6 [11264181.001]
  • [Cites] Clin Infect Dis. 2002 Feb 15;34(4):559-60 [11797191.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):471-7 [12580962.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Acta Otolaryngol. 2004 Apr;124(3):318-23 [15141762.001]
  • [Cites] J Gen Virol. 1987 Nov;68 ( Pt 11):2853-62 [2824665.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3261-6 [1317726.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1396-403 [7858270.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):17-23 [8546204.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]
  • [Cites] Arch Dermatol. 1998 Jun;134(6):751 [9645650.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] J Cutan Pathol. 2005 Jan;32(1):21-7 [15660651.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):626-8 [15917415.001]
  • (PMID = 18628086.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / 5R01CA082274; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / U01 CA121947-016821; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / R01 CA121935; United States / NCI NIH HHS / CA / CA121947-016821
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS125501; NLM/ PMC2718775
  •  go-up   go-down


35. Chen W, Hilton IB, Staudt MR, Burd CE, Dittmer DP: Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas. J Virol; 2010 Apr;84(8):3898-908
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas.
  • The role of p53 in primary effusion lymphoma (PEL) is complicated.
  • The latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus (KSHV) binds p53.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • [Cites] J Virol. 2003 Jun;77(12):7093-100 [12768028.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):371-81 [14667504.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1010-4 [14963330.001]
  • [Cites] Virology. 2004 Feb 20;319(2):225-36 [14980483.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16822-31 [14742422.001]
  • [Cites] J Virol. 2004 Sep;78(18):10074-85 [15331740.001]
  • [Cites] J Virol. 2004 Oct;78(19):10336-47 [15367600.001]
  • [Cites] J Virol. 2004 Oct;78(19):10348-59 [15367601.001]
  • [Cites] J Virol. 2004 Oct;78(20):11121-9 [15452232.001]
  • [Cites] J Virol. 2004 Nov;78(22):12566-75 [15507644.001]
  • [Cites] Nature. 1979 Mar 15;278(5701):261-3 [218111.001]
  • [Cites] Cell. 1979 May;17(1):43-52 [222475.001]
  • [Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]
  • [Cites] Cell. 1983 Nov;35(1):79-87 [6313230.001]
  • [Cites] Nature. 1987 Oct 1-7;329(6138):456-8 [3309672.001]
  • [Cites] Nature. 1987 Oct 1-7;329(6138):458-60 [2821401.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] J Virol. 1991 Oct;65(10):5417-24 [1895390.001]
  • [Cites] Genes Dev. 1991 Dec;5(12B):2375-85 [1752433.001]
  • [Cites] Virology. 1992 Mar;187(1):343-7 [1736539.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]
  • [Cites] Genes Dev. 1992 Oct;6(10):1886-98 [1398068.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):847-9 [8479522.001]
  • [Cites] Nat Genet. 1993 May;4(1):42-6 [8099841.001]
  • [Cites] Genes Dev. 1993 Jul;7(7A):1126-32 [8319905.001]
  • [Cites] FASEB J. 1993 Jul;7(10):951-6 [8344493.001]
  • [Cites] J Virol. 1994 May;68(5):2869-78 [8151757.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4407-11 [7753819.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5349-57 [8895579.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] Science. 1996 Nov 8;274(5289):948-53 [8875929.001]
  • [Cites] Nature. 1997 May 15;387(6630):296-9 [9153395.001]
  • [Cites] Nature. 1997 May 15;387(6630):299-303 [9153396.001]
  • [Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]
  • [Cites] J Virol. 1999 Dec;73(12):9789-95 [10559289.001]
  • [Cites] J Clin Invest. 1997 Nov 15;100(10):2606-10 [9366576.001]
  • [Cites] Oncogene. 1998 Mar;16(11):1429-41 [9525742.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] J Virol. 1998 Oct;72(10):8143-9 [9733855.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3077-80 [10077639.001]
  • [Cites] J Hum Virol. 1997 Nov-Dec;1(1):19-29 [10195227.001]
  • [Cites] FEBS Lett. 1999 Mar 19;447(1):5-9 [10218570.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] J Virol. 1999 Jun;73(6):5149-55 [10233979.001]
  • [Cites] J Virol. 2004 Dec;78(24):14033-8 [15564510.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3862-74 [15525642.001]
  • [Cites] J Virol. 2005 Mar;79(6):3468-78 [15731241.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] J Virol. 2005 Jun;79(12):7453-65 [15919901.001]
  • [Cites] J Virol. 2005 Nov;79(21):13618-29 [16227282.001]
  • [Cites] J Virol. 2005 Nov;79(21):13829-36 [16227305.001]
  • [Cites] J Virol. 2006 Jan;80(2):697-709 [16378973.001]
  • [Cites] Science. 2006 Feb 10;311(5762):856-61 [16469929.001]
  • [Cites] J Virol. 2006 Mar;80(5):2243-56 [16474132.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3169-76 [16540668.001]
  • [Cites] Blood. 2006 May 15;107(10):4122-9 [16439677.001]
  • [Cites] J Virol. 2006 Jun;80(11):5273-82 [16699007.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1963-73 [16794734.001]
  • [Cites] J Virol. 2006 Sep;80(18):9017-30 [16940514.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14554-9 [16983096.001]
  • [Cites] J Virol. 2006 Nov;80(21):10772-86 [16928766.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e116 [17069461.001]
  • [Cites] Virology. 2007 Jan 20;357(2):149-57 [16979209.001]
  • [Cites] J Virol. 2007 Feb;81(4):1912-22 [17121789.001]
  • [Cites] J Virol. 2007 Apr;81(8):4348-56 [17287261.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):1019-28 [17364023.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12365-70 [17640893.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):452-7 [17762570.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2886-95 [18633130.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3827-34 [18682598.001]
  • [Cites] Virology. 1999 Nov 25;264(2):254-64 [10562490.001]
  • [Cites] J Gen Virol. 1999 Nov;80 ( Pt 11):2889-900 [10580050.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1857-68 [10601360.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(3):1001-7 [10629057.001]
  • [Cites] J Biol Chem. 2000 Mar 24;275(12):8945-51 [10722742.001]
  • [Cites] Oncogene. 2000 Mar 9;19(11):1473-6 [10723139.001]
  • [Cites] J Virol. 2000 Sep;74(18):8532-40 [10954554.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):28039-44 [10827196.001]
  • [Cites] Nat Cell Biol. 2000 Sep;2(9):563-8 [10980695.001]
  • [Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] J Gen Virol. 2000 Nov;81(Pt 11):2645-52 [11038375.001]
  • [Cites] J Virol. 2001 Jan;75(1):458-68 [11119614.001]
  • [Cites] J Virol. 2001 Feb;75(4):1798-807 [11160678.001]
  • [Cites] J Virol. 2001 Apr;75(7):3250-8 [11238851.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22971-8 [11313352.001]
  • [Cites] J Virol. 2001 Sep;75(17):7882-92 [11483733.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):31016-22 [11425857.001]
  • [Cites] J Virol. 2001 Sep;75(18):8761-71 [11507221.001]
  • [Cites] J Virol. 2001 Oct;75(19):9446-57 [11533207.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3076-84 [11753987.001]
  • [Cites] J Gen Virol. 2002 Jan;83(Pt 1):179-88 [11752715.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27401-11 [12015325.001]
  • [Cites] J Virol. 2002 Nov;76(22):11596-604 [12388720.001]
  • [Cites] J Virol. 2002 Dec;76(24):12917-24 [12438617.001]
  • (PMID = 20130056.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA109232-04; United States / NCI NIH HHS / CA / CA109232-03; United States / NCI NIH HHS / CA / T32 CA009156; United States / NCI NIH HHS / CA / CA009156; United States / NCI NIH HHS / CA / CA109232-01; United States / NCI NIH HHS / CA / CA109232-02; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232-02; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / R01 CA109232-01; United States / NCI NIH HHS / CA / R01 CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232-03; United States / NCI NIH HHS / CA / CA109232-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / latency-associated nuclear antigen
  • [Other-IDs] NLM/ PMC2849491
  •  go-up   go-down


36. Osorio S G, Montenegro U C: [Lymphomas and HIV infection in a reference hospital of Santiago, Chile: 1990-2002: report of 14 cases and review]. Rev Chilena Infectol; 2007 Apr;24(2):117-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphomas and HIV infection in a reference hospital of Santiago, Chile: 1990-2002: report of 14 cases and review].
  • [Transliterated title] Linfomas asociados a infección por virus de inmunodeficiencia humana en un complejo hospitalario de la Región Metropolitana, Chile: 1990-2002. Reporte de 14 casos y revisión.
  • The association of HIV infection and lymphoma in patients attending at the South Health Metropolitan Reference Centre is presented.
  • RESULTS: 14 cases were detected, 10 non Hodgkin lymphoma patients (7 with high malignancy and 50% in stages III-IVB) and 4 with Hodgkin lymphoma (3 with mixed cellularity, 2 in stage IVB).
  • Ten patients were classified under stage C3 of AIDS CDC criteria, the mean CD4 count was 139 cells/mm3 and mean CV was 5,32 log.
  • Eighty six percent of patients presented with unique or multiples lymphonodes, with predominance of advanced lymphoma stage.
  • Conventional CHOP chemotherapy was the treatment for high risk and extended non Hodgkin lymphomas and for extended Hodgkin lymphomas the ABVD protocol was administered.
  • Global mortality in this series was 71%, attributable to tumor disease per se or to sepsis.
  • Four patients survived (18 to 50 months) in complete remission, 2 non Hodgkin lymphomas and 2 Hodgkin lymphomas.
  • The low incidence of lymphoma and AIDS association and the high frequency of lymphomas with localized or generalized lymphonodes in this series are remarkable.
  • [MeSH-major] Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Chile / epidemiology. Female. Hodgkin Disease / diagnosis. Hodgkin Disease / drug therapy. Hodgkin Disease / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453069.001).
  • [ISSN] 0716-1018
  • [Journal-full-title] Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
  • [ISO-abbreviation] Rev Chilena Infectol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Number-of-references] 30
  •  go-up   go-down


37. Benicchi T, Ghidini C, Re A, Cattaneo C, Casari S, Caimi L, Rossi G, Imberti L: T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma. Transplantation; 2005 Sep 15;80(5):673-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma.
  • BACKGROUND: One of the major concern for high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT) for HIV-associated lymphoma is that posttransplant immunosuppression might worsen immune defects of HIV individuals.
  • Since the introduction of highly active antiretroviral therapy has made HSCT possible also in these patients, we analyzed whether the immune system already compromised by HIV infection might support an efficient T-cell recovery after HSCT.
  • METHODS: The kinetics and the extent of T-cell reconstitution were investigated before and after HSCT in four patients with HIV-related lymphoma (one with Hodgkin's Disease and three with non-Hodgkin's lymphoma) by measuring the thymic output, the level of IL-7 and the heterogeneity of T-cell repertoire.
  • CONCLUSIONS: High-dose therapy and HSCT in HIV patients under highly active antiretroviral therapy does not worsen the immune defects.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / therapy


38. Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, PETHEMA, GELTAMO, GELCAB and GESIDA Groups: Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol; 2008 Feb;140(4):411-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
  • Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma.
  • This phase II trial aimed to evaluate the safety and efficacy of six cycles of R-CHOP in patients with HIV-related DLBCL and to determine whether response to highly active antiretroviral therapy (HAART) had prognostic impact.
  • Complete response was achieved in 55 (69%) patients, with an estimated 3-year disease-free survival of 77% and 3-year overall survival of 56%.
  • In HIV-related DLBCL R-CHOP is feasible, safe and effective.
  • The prognosis depends on lymphoma-related parameters and on the response to HAART.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162120.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


39. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, Alvarnas J, Lacey SF, Yee JK, Li M, Couture L, Hsu D, Forman SJ, Rossi JJ, Zaia JA: RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med; 2010 Jun 16;2(36):36ra43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.
  • AIDS patients who develop lymphoma are often treated with transplanted hematopoietic progenitor cells.
  • As a first step in developing a hematopoietic cell-based gene therapy treatment, four patients undergoing treatment with these transplanted cells were also given gene-modified peripheral blood-derived (CD34(+)) hematopoietic progenitor cells expressing three RNA-based anti-HIV moieties (tat/rev short hairpin RNA, TAR decoy, and CCR5 ribozyme).
  • In vitro estimates of successful expression of the anti-HIV moieties were initially as high as 22% but declined to approximately 1% over 4 weeks of culture.
  • Transfected cells were successfully engrafted in all four infused patients by day 11, and there were no unexpected infusion-related toxicities.
  • These results support the development of an RNA-based cell therapy platform for HIV.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2007 Dec;25(12):1444-54 [18066041.001]
  • [Cites] Mol Ther. 2007 Jun;15(6):1182-8 [17406343.001]
  • [Cites] Hum Gene Ther. 2008 Jun;19(6):622-34 [18533892.001]
  • [Cites] J Gene Med. 2008 Oct;10(10):1059-70 [18642399.001]
  • [Cites] Gene Ther. 2008 Dec;15(23):1536-49 [18800151.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] Nat Med. 2009 Mar;15(3):285-92 [19219022.001]
  • [Cites] Science. 2009 Mar 6;323(5919):1304-7 [19265012.001]
  • [Cites] Mol Ther. 2009 May;17(5):844-50 [19259065.001]
  • [Cites] Science. 2009 Nov 6;326(5954):818-23 [19892975.001]
  • [Cites] Gene Ther. 2010 Mar;17(3):389-99 [19865182.001]
  • [Cites] Blood. 2002 Jan 15;99(2):698-701 [11781257.001]
  • [Cites] Mol Ther. 2002 Apr;5(4):479-84 [11945076.001]
  • [Cites] Gene Ther. 2002 Aug;9(16):1055-64 [12140733.001]
  • [Cites] Gene Ther. 2002 Dec;9(24):1730-4 [12457288.001]
  • [Cites] Mol Ther. 2003 Mar;7(3):325-33 [12668128.001]
  • [Cites] Mol Ther. 2003 Jul;8(1):62-71 [12842429.001]
  • [Cites] Mol Ther. 2003 Aug;8(2):196-206 [12907142.001]
  • [Cites] Blood. 2004 Feb 1;103(3):796-803 [12920024.001]
  • [Cites] Hum Gene Ther. 2004 Mar;15(3):251-62 [15018734.001]
  • [Cites] J Gene Med. 2004 Mar;6(3):268-77 [15026988.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):395-6 [3166513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9870-4 [1409715.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Jul 15;84(2):421-32 [7517715.001]
  • [Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4618-28 [8639830.001]
  • [Cites] Gene Ther. 1996 Aug;3(8):717-24 [8854097.001]
  • [Cites] J Virol. 1997 Jun;71(6):4707-16 [9151864.001]
  • [Cites] J Virol. 1999 May;73(5):3649-60 [10196257.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] Clin Immunol. 2005 Apr;115(1):26-32 [15870017.001]
  • [Cites] Mol Ther. 2005 Jul;12(1):77-86 [15963923.001]
  • [Cites] Mol Ther. 2005 Oct;12(4):697-706 [16039909.001]
  • [Cites] Mol Ther. 2005 Nov;12(5):900-9 [16115802.001]
  • [Cites] Mol Ther. 2006 Feb;13(2):366-73 [16325473.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1751-60 [16269617.001]
  • [Cites] Clin Infect Dis. 2006 Apr 1;42(7):1003-10 [16511767.001]
  • [Cites] Mol Ther. 2006 Oct;14(4):494-504 [16844419.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3305-12 [16857988.001]
  • [Cites] Mol Ther. 2007 May;15(5):1024-33 [17356541.001]
  • [Cites] Methods Mol Biol. 2008;434:99-112 [18470641.001]
  • (PMID = 20555022.001).
  • [ISSN] 1946-6242
  • [Journal-full-title] Science translational medicine
  • [ISO-abbreviation] Sci Transl Med
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000043-49; United States / NIAID NIH HHS / AI / AI61839; United States / NHLBI NIH HHS / HL / R01 HL074704; United States / NIAID NIH HHS / AI / AI42552; United States / NCI NIH HHS / CA / CA107399-05; United States / NIAID NIH HHS / AI / P01 AI061839-04; United States / NIAID NIH HHS / AI / R37 AI029329; United States / NCRR NIH HHS / RR / RR000043-49; United States / NIAID NIH HHS / AI / AI061839-04; United States / NHLBI NIH HHS / HL / HL07470; United States / NCI NIH HHS / CA / P50 CA107399-05; United States / NCRR NIH HHS / RR / M01 RR00043; United States / NCRR NIH HHS / RR / RR025083-01; United States / NCI NIH HHS / CA / P30 CA33572-26; United States / NCRR NIH HHS / RR / S10 RR025083-01; United States / NIAID NIH HHS / AI / AI042552-11; United States / NCI NIH HHS / CA / P30 CA033572-29; United States / NCRR NIH HHS / RR / M01 RR000043; United States / NHLBI NIH HHS / HL / R01 HL074704-07; United States / NIAID NIH HHS / AI / P01 AI061839; United States / NCI NIH HHS / CA / P30 CA033572; United States / NIAID NIH HHS / AI / R01 AI042552; United States / NCRR NIH HHS / RR / S10 RR025083; United States / NIAID NIH HHS / AI / R01 AI042552-11; United States / NCRR NIH HHS / RR / S10RR025083-01; United States / NHLBI NIH HHS / HL / HL074704-07; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 63231-63-0 / RNA
  • [Other-IDs] NLM/ NIHMS305014; NLM/ PMC3130552
  •  go-up   go-down


40. Cobo F, Talavera P, Busquier H, Concha A: CNK/T-cell brain lymphoma associated with Epstein-Barr virus in a patient with AIDS. Neuropathology; 2007 Aug;27(4):396-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNK/T-cell brain lymphoma associated with Epstein-Barr virus in a patient with AIDS.
  • We report a case of extranodal NK/T-cell lymphoma, nasal type, with exclusive cerebral localization in a patient with AIDS.
  • A diagnosis of extranodal NK/T-cell lymphoma was made and the patient died a few days later.
  • This case represents a very rare example of NK/T-cell lymphoma of the brain in a patient with AIDS.
  • The diagnosis of this kind of lymphomas requires a multimodality approach correlating clinical, morphological, immunophenotypic and molecular data.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Epstein-Barr Virus Infections / complications. Killer Cells, Natural / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / pathology. Adult. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Brain Neoplasms / virology. Diagnosis, Differential. Gene Rearrangement, T-Lymphocyte. Hepatitis C / complications. Herpesvirus 4, Human / genetics. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Polymerase Chain Reaction


41. Pantanowitz L, Wu Z, Dezube BJ, Pihan G: Extracavitary primary effusion lymphoma of the anorectum. Clin Lymphoma Myeloma; 2005 Sep;6(2):149-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracavitary primary effusion lymphoma of the anorectum.
  • We report a case of an extracavitary primary effusion lymphoma occurring in the anorectum of a patient with advanced acquired immune deficiency syndrome.
  • The morphology, null cell immunophenotype, and acquisition of plasma cell markers in this case are typical of the so-called solid variant of primary effusion lymphoma.
  • Lymphoma cells in this case were shown to be co-infected with human herpesvirus-8 and Epstein-Barr virus.
  • The purpose of this report is to add another case to the emerging literature regarding the heterogeneous category of extraserous human herpesvirus-8-associated lymphomas.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. HIV Infections / pathology. Herpesvirus 4, Human. Herpesvirus 8, Human. Lymphoma, AIDS-Related / pathology. Rectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231856.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Sarek G, Järviluoma A, Ojala PM: KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood; 2006 Jan 15;107(2):725-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas.
  • Kaposi sarcoma herpesvirus (KSHV) infection is consistently associated with primary effusion lymphomas (PELs) that are non-Hodgkin lymphomas of B-cell origin.
  • Here we demonstrate that v-cyclin together with its kinase partner CDK6 phosphorylates the associated p27(KIP1) in PEL cells, which represent a biologically relevant model system for KSHV pathobiology.
  • [MeSH-major] Cell Proliferation. Cyclin-Dependent Kinase Inhibitor p27 / antagonists & inhibitors. Herpesvirus 8, Human / metabolism. Lymphoma, AIDS-Related / metabolism. Sarcoma, Kaposi / metabolism. Viral Proteins / pharmacology

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. L-Threonine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160006.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclins; 0 / HHV8-Vcyc protein, Human herpesvirus 8; 0 / Viral Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 2ZD004190S / Threonine; 452VLY9402 / Serine; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6
  •  go-up   go-down


43. Xu D, Zhao L, Del Valle L, Miklossy J, Zhang L: Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. J Virol; 2008 Jul;82(13):6251-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV) infection is associated with many human malignancies.
  • We find that high levels of IRF-4 are associated with EBV transformation of human primary B cells in vitro and with EBV type III latency in which LMP-1 is expressed.
  • Finally, IRF-4 is expressed in significant numbers of specimens of primary central nervous system (CNS) lymphomas (12/27 [44.4%]), an EBV-associated malignancy.
  • The association between the expression levels of LMP-1 and IRF-4 is statistically significant (P = 0.011) in these CNS lymphomas.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Feb;74(3):1061-8 [10627515.001]
  • [Cites] J Virol. 2000 Apr;74(7):3388-98 [10708456.001]
  • [Cites] J Exp Med. 2000 Apr 17;191(8):1281-92 [10770796.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6055-60 [10811897.001]
  • [Cites] AIDS Read. 2000 Aug;10(8):486-91 [10967810.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3323-4 [11013270.001]
  • [Cites] J Virol. 2001 Jan;75(1):341-50 [11119603.001]
  • [Cites] Annu Rev Immunol. 2001;19:623-55 [11244049.001]
  • [Cites] J Virol. 2001 Dec;75(24):12393-401 [11711629.001]
  • [Cites] J Gen Virol. 2001 Dec;82(Pt 12):3057-66 [11714984.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jan;22(1):121-33 [11846983.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Oncogene. 2002 Apr 25;21(18):2914-8 [11973653.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):3120-30 [12218129.001]
  • [Cites] J Virol. 2002 Oct;76(20):10427-36 [12239319.001]
  • [Cites] Genes Dev. 2003 Jul 15;17(14):1703-8 [12832394.001]
  • [Cites] Nat Cell Biol. 2003 Sep;5(9):834-9 [12942087.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6424-31 [14559832.001]
  • [Cites] J Virol. 2004 Apr;78(8):4108-19 [15047827.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2774-84 [15077141.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2797-808 [15077143.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2950-66 [15077156.001]
  • [Cites] J Natl Cancer Inst. 2004 May 5;96(9):662-72 [15126603.001]
  • [Cites] J Virol Methods. 2004 Jun 1;118(1):9-13 [15158063.001]
  • [Cites] Virology. 2004 May 20;323(1):141-52 [15165826.001]
  • [Cites] J Exp Med. 2004 Jul 19;200(2):247-53 [15249594.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):46335-42 [15322136.001]
  • [Cites] Int J Cancer. 1977 Jan;19(1):27-33 [188769.001]
  • [Cites] Arch Pathol Lab Med. 1997 Dec;121(12):1287-91 [9431321.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1700-9 [9501091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3621-6 [9520415.001]
  • [Cites] Biochimie. 1998 Aug-Sep;80(8-9):651-8 [9865487.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):3216-23 [10082588.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jul 5;260(2):329-31 [10403770.001]
  • [Cites] J Virol. 2004 Dec;78(23):12987-95 [15542650.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2573-81 [15728463.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7403-12 [16103093.001]
  • [Cites] J Biol Chem. 2006 Apr 7;281(14):9163-9 [16469740.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 May;6(5):775-84 [16759167.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3402-7 [17360658.001]
  • [Cites] J Virol. 2007 Jun;81(11):6068-78 [17376914.001]
  • [Cites] J Virol. 2007 Sep;81(18):9748-58 [17609264.001]
  • [Cites] J Virol. 1990 May;64(5):2126-34 [2157875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Apr;80(7):1987-91 [6300885.001]
  • [Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]
  • [Cites] Virology. 1985 Mar;141(2):221-34 [3002016.001]
  • [Cites] J Virol. 1986 Apr;58(1):233-7 [3005654.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(22):8060-4 [2825176.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(23):9558-62 [2556717.001]
  • [Cites] EMBO J. 1990 Jan;9(1):147-52 [2153074.001]
  • [Cites] J Virol. 1990 Apr;64(4):1855-8 [2157069.001]
  • [Cites] J Virol. 1990 May;64(5):2309-18 [2157887.001]
  • [Cites] J Virol. 1990 Jul;64(7):3407-16 [2352328.001]
  • [Cites] J Virol. 1991 Jul;65(7):3958-63 [1645805.001]
  • [Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]
  • [Cites] J Virol. 1991 Dec;65(12):6765-71 [1658373.001]
  • [Cites] Mol Cell Biol. 1992 Nov;12(11):4930-6 [1406670.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):3976-85 [8358726.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9150-4 [8415670.001]
  • [Cites] Cell. 1993 Nov 19;75(4):641-52 [8242740.001]
  • [Cites] J Virol. 1995 Jul;69(7):4390-8 [7769701.001]
  • [Cites] Genes Dev. 1995 Jun 1;9(11):1377-87 [7797077.001]
  • [Cites] J Cancer Res Clin Oncol. 1995;121(9-10):516-20 [7559730.001]
  • [Cites] J Virol. 1996 Jan;70(1):623-7 [8523583.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1283-94 [8657101.001]
  • [Cites] Clin Neuropathol. 1996 Mar-Apr;15(2):79-86 [8925601.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Dec 24;229(3):838-44 [8954981.001]
  • [Cites] J Virol. 1996 Dec;70(12):8653-9 [8970991.001]
  • [Cites] Science. 1997 Jan 24;275(5299):540-3 [8999800.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1447-52 [9037073.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):5748-57 [9315633.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):226-30 [9326949.001]
  • [Cites] EMBO J. 1997 Oct 15;16(20):6131-40 [9359753.001]
  • [Cites] Oncogene. 1997 Oct 16;15(16):1979-85 [9365244.001]
  • [Cites] Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):573-80 [10591086.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6959-64 [10602470.001]
  • (PMID = 18417578.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108951; United States / NCRR NIH HHS / RR / RR15635; United States / NIAID NIH HHS / AI / R21 AI059132; United States / NCRR NIH HHS / RR / P20 RR015635; United States / NCI NIH HHS / CA / CA108951; United States / NIAID NIH HHS / AI / AI59132
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Interferon Regulatory Factors; 0 / Viral Matrix Proteins; 0 / interferon regulatory factor-4
  • [Other-IDs] NLM/ PMC2447047
  •  go-up   go-down


44. Singh J, Malani AK, Ganguly S, Kambhampati S: HAART- and AIDS-related lymphomas. Blood; 2006 Nov 15;108(10):3621; author reply 3621-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HAART- and AIDS-related lymphomas.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • (PMID = 17085718.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


45. Serraino D, Zucchetto A, Suligoi B, Bruzzone S, Camoni L, Boros S, De Paoli A, Dal Maso L, Franceschi S, Rezza G: Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study. J Acquir Immune Defic Syndr; 2009 Sep 1;52(1):99-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study.
  • OBJECTIVES: To provide survival estimates of Italian people with AIDS (PWA) in the highly active antiretroviral therapy era and to identify prognostic factors at diagnosis and illnesses present at death.
  • Non-Hodgkin lymphoma at AIDS diagnosis was the strongest negative prognostic factor, particularly in the first 12 months after AIDS (hazard ratio = 9.2, for primary brain lymphoma).
  • At death, non-AIDS-defining illnesses increased from 38.4% in 1999 to 56.9% in 2006, with non-AIDS-defining cancers rising from 3.7% to 8.7%.
  • CONCLUSIONS: Our study documented the prolonged survival of Italian PWA, the strong impact of non-Hodgkin lymphoma on mortality, and the increasing frequency of non-AIDS-defining illnesses at death.
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / mortality. Female. Humans. Italy / epidemiology. Longitudinal Studies. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / mortality. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448558.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. D'Souza GA, Sunad R, Rajagopalan N, Ananthamurthy A, Murthy KR, Babu K: NK/T-cell lymphoma in AIDS. J Assoc Physicians India; 2006 Nov;54:890-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK/T-cell lymphoma in AIDS.
  • A 42-year-old man diagnosed to be HIV positive and on highly active antiretroviral treatment (HAART), presented with double vision and gradual drooping of the left eyelid.
  • Further workup showed the mass to be an NK/T cell lymphoma.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, T-Cell / diagnosis. Nose Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249261.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


47. Ferrazzo KL, Mesquita RA, Aburad AT, Nunes FD, de Sousa SO: EBV detection in HIV-related oral plasmablastic lymphoma. Oral Dis; 2007 Nov;13(6):564-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV detection in HIV-related oral plasmablastic lymphoma.
  • OBJECTIVES: Plasmablastic lymphoma (PBL) of the oral cavity is an aggressive neoplasm derived from B cell, considered to be the second more common among human immunodeficiency virus (HIV)-associated malignancies.
  • As Epstein-Barr virus (EBV) infection has been associated with this neoplasm, the aim of the present study was to assess the presence of EBV in 11 cases of oral HIV-related PBL and investigate the controversial issue of the presence of Human herpesvirus-8 (HHV-8) in these tumors.
  • METHODS: DNA was extracted from nine cases of HIV-associated oral lymphomas, diagnosed as PBL, and genomic material was amplified by polymerase chain reaction to verify the presence of EBV.
  • CONCLUSION: The presence of EBV in all cases studied favors a direct role of this virus in the development of HIV-related PBL, and this finding could be considered when dealing with HIV patients.
  • [MeSH-major] DNA, Viral / analysis. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology. Mouth Neoplasms / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17944673.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


48. Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL: Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol; 2005 Dec;29(12):1633-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm.
  • AIDS-associated aggressive B-cell lymphomas often have plasmacytoid features.
  • Plasma cell neoplasms in HIV patients were commonly described to have atypical morphology and an aggressive clinical course in the literature.
  • We reviewed 14 cases of neoplasms with marked plasmacytic differentiation in HIV-positive patients to determine their clinicopathologic features.
  • The 14th patient who had a nodal disease with more undifferentiated morphology and expression of the HHV8 LNA protein was alive without disease at last follow-up (>72 months), probably representing a novel HHV8(+) lymphoma.
  • We conclude that most plasmacytic tumors in HIV-positive individuals are extramedullary, clinically aggressive EBV(+) tumors identical to plasmablastic lymphoma that does not have the clinical features of plasma cell myeloma.
  • [MeSH-major] HIV Seropositivity. Herpesvirus 4, Human / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, AIDS-Related / virology. Multiple Myeloma / pathology


49. Kang KM, Song DS, Park JM, Jung CK, Hong YS, Kang MW, Park CW: Four cases of non-Hodgkin's lymphoma in AIDS patients. Korean J Intern Med; 2006 Dec;21(4):266-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four cases of non-Hodgkin's lymphoma in AIDS patients.
  • The incidence of opportunistic infection has decreased since the introduction of highly active antiretroviral therapy, so lymphoma is now far and away the most lethal complication of acquired immunodeficiency syndrome.
  • We have experienced four cases of NHL in AIDS patients.
  • The first patient was a 37 year old male who presented with left sided hemiplegia due to CNS lymphoma.
  • The second patient was a 40 year old male who was admitted because of jaundice; he was diagnosed as having lymphoma that exclusively involved the liver.
  • The third patient was a 38-year-old male who presented with palpable mass in the left cervical region, which was diagnosed as lymphoma.
  • Above three cases were confirmed as diffuse large B cell lymphoma.
  • The latter case is the first report of NHL involving the chest wall musculature in a Korean AIDS patient.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, Non-Hodgkin / complications

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):863-73 [11298581.001]
  • [Cites] Korean J Intern Med. 2001 Mar;16(1):1-7 [11417298.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):430-5 [11433410.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):349-51 [12688356.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1981 Jun 5;30(21):250-2 [6265753.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] JAMA. 1989 Feb 3;261(5):719-24 [2536124.001]
  • [Cites] Ann Intern Med. 1990 Aug 15;113(4):276-82 [1973886.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):515-24 [9711914.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • (PMID = 17249512.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3891035
  •  go-up   go-down


50. Trobridge GD, Wu RA, Beard BC, Chiu SY, Muñoz NM, von Laer D, Rossi JJ, Kiem HP: Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One; 2009 Nov 02;4(11):e7693
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection.
  • BACKGROUND: There is currently no effective AIDS vaccine, emphasizing the importance of developing alternative therapies.
  • Recently, a patient was successfully transplanted with allogeneic, naturally resistant CCR5-negative (CCR5Delta32) cells, setting the stage for transplantation of naturally resistant, or genetically modified stem cells as a viable therapy for AIDS.
  • Hematopoietic stem cell (HSC) gene therapy using vectors that express various anti-HIV transgenes has also been attempted in clinical trials, but inefficient gene transfer in these studies has severely limited the potential of this approach.
  • Here we evaluated HSC gene transfer of an anti-HIV vector in the pigtailed macaque (Macaca nemestrina) model, which closely models human transplantation.
  • METHODS AND FINDINGS: We used lentiviral vectors that inhibited both HIV-1 and simian immunodeficiency virus (SIV)/HIV-1 (SHIV) chimera virus infection, and also expressed a P140K mutant methylguanine methyltransferase (MGMT) transgene to select gene-modified cells by adding chemotherapy drugs.
  • The high marking levels allowed us to demonstrate protection from SHIV in lymphocytes derived from gene-modified macaque long-term repopulating cells that expressed an HIV-1 fusion inhibitor.
  • We observed a statistically significant 4-fold increase of gene-modified cells after challenge of lymphocytes from one macaque that received stem cells transduced with an anti-HIV vector (p<0.02, Student's t-test), but not in lymphocytes from a macaque that received a control vector.
  • We also established a competitive repopulation assay in a second macaque for preclinical testing of promising anti-HIV vectors.
  • The vectors we used were HIV-based and thus efficiently transduce human cells, and the transgenes we used target HIV-1 genes that are also in SHIV, so our findings can be rapidly translated to the clinic.
  • CONCLUSIONS: Here we demonstrate the ability to select protected HSC-derived lymphocytes in vivo in a clinically relevant nonhuman primate model of HIV/SHIV infection.
  • This approach can now be evaluated in human clinical trials in AIDS lymphoma patients.
  • In this patient setting, chemotherapy would not only kill malignant cells, but would also increase the number of MGMTP140K-expressing HIV-resistant cells.
  • This approach should allow for high levels of HIV-protected cells in AIDS patients to evaluate AIDS gene therapy.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2002 Jul 10;288(2):222-35 [12095387.001]
  • [Cites] Gene Ther. 2010 Jan;17(1):37-49 [19741733.001]
  • [Cites] J Med Primatol. 2002 Aug;31(4-5):237-56 [12390546.001]
  • [Cites] Science. 2003 Jun 13;300(5626):1749-51 [12805549.001]
  • [Cites] Science. 2003 Jun 27;300(5628):2036-9 [12829768.001]
  • [Cites] Nat Rev Drug Discov. 2003 Aug;2(8):624-34 [12904812.001]
  • [Cites] Mol Ther. 2003 Aug;8(2):196-206 [12907142.001]
  • [Cites] J Clin Invest. 2003 Nov;112(10):1581-8 [14617759.001]
  • [Cites] J Virol. 2004 Jan;78(2):568-75 [14694088.001]
  • [Cites] Hum Gene Ther. 2004 Mar;15(3):251-62 [15018734.001]
  • [Cites] Curr Gene Ther. 2004 Mar;4(1):15-31 [15032611.001]
  • [Cites] Blood. 2004 May 15;103(10):3710-6 [14739227.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4062-9 [14976042.001]
  • [Cites] J Immunol. 1985 Feb;134(2):971-6 [3871222.001]
  • [Cites] Immunogenetics. 1985;21(3):235-46 [3872841.001]
  • [Cites] Hum Gene Ther. 1999 Nov 20;10(17):2769-78 [10584923.001]
  • [Cites] Microbes Infect. 2000 Feb;2(2):223-9 [10742694.001]
  • [Cites] AIDS. 1999;13 Suppl A:S113-20 [10885770.001]
  • [Cites] Hum Gene Ther. 2000 Sep 20;11(14):2025-37 [11020801.001]
  • [Cites] Ann N Y Acad Sci. 2000 Nov;918:318-29 [11131719.001]
  • [Cites] J Pharmacol Exp Ther. 2001 May;297(2):524-30 [11303039.001]
  • [Cites] Hum Gene Ther. 2001 Jun 10;12(9):1013-9 [11399224.001]
  • [Cites] Mol Ther. 2002 Jan;5(1):33-41 [11786043.001]
  • [Cites] J Virol. 1992 Apr;66(4):2232-9 [1548759.001]
  • [Cites] J Virol. 1992 Dec;66(12):7517-21 [1433527.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6221-7 [7954470.001]
  • [Cites] J Med Primatol. 1996 Jun;25(3):163-74 [8892037.001]
  • [Cites] J Virol. 1997 May;71(5):3932-9 [9094670.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1936-45 [9581836.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Curr Opin Biotechnol. 1998 Oct;9(5):457-63 [9821272.001]
  • [Cites] Science. 1999 Jan 29;283(5402):682-6 [9924027.001]
  • [Cites] Blood. 2005 Feb 1;105(3):997-1002 [15494421.001]
  • [Cites] Methods Mol Biol. 2005;309:261-72 [15990406.001]
  • [Cites] Hum Gene Ther. 2005 Dec;16(12):1355-66 [16390267.001]
  • [Cites] Nature. 2006 May 25;441(7092):537-41 [16724069.001]
  • [Cites] Nat Biotechnol. 2006 Jun;24(6):687-96 [16732270.001]
  • [Cites] Hum Gene Ther. 2006 Jun;17(6):577-88 [16776567.001]
  • [Cites] Mol Ther. 2006 Oct;14(4):494-504 [16844419.001]
  • [Cites] Retrovirology. 2006;3:76 [17078891.001]
  • [Cites] Mol Ther. 2007 Jan;15(1):76-85 [17164778.001]
  • [Cites] Blood. 2007 Jan 1;109(1):65-70 [16968897.001]
  • [Cites] J Virol. 2007 Mar;81(6):2700-12 [17182671.001]
  • [Cites] PLoS Pathog. 2007 Apr;3(4):e54 [17432934.001]
  • [Cites] Hum Gene Ther. 2007 May;18(5):451-6 [17536975.001]
  • [Cites] Exp Hematol. 2007 Jul;35(7):1132-9 [17588482.001]
  • [Cites] J Virol. 2007 Nov;81(22):12210-7 [17804491.001]
  • [Cites] Nat Med. 2007 Dec;13(12):1389-90 [18064013.001]
  • [Cites] Nat Biotechnol. 2007 Dec;25(12):1444-54 [18066041.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5537-43 [18388180.001]
  • [Cites] Gene Ther. 2008 Dec;15(23):1536-49 [18800151.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] Nat Med. 2009 Mar;15(3):285-92 [19219022.001]
  • [Cites] Hum Gene Ther. 2009 Apr;20(4):325-36 [19267665.001]
  • [Cites] Cell. 2002 Aug 23;110(4):521-9 [12202041.001]
  • (PMID = 19888329.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK047754; United States / NIAID NIH HHS / AI / R21 AI063959; United States / NIAID NIH HHS / AI / AI063959; United States / NIAID NIH HHS / AI / AI061839; United States / NHLBI NIH HHS / HL / P01 HL053750; United States / NIDDK NIH HHS / DK / DK056465; United States / NIDDK NIH HHS / DK / DK047754; United States / NIDDK NIH HHS / DK / P30 DK056465; United States / NIAID NIH HHS / AI / R01 AI080326; United States / NIAID NIH HHS / AI / P01 AI061839; United States / NHLBI NIH HHS / HL / HL053750
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AIDS Vaccines
  • [Other-IDs] NLM/ PMC2765621
  •  go-up   go-down


51. Madan RA, Chang VT, Dever LL: An uncommon presentation of HIV-related lymphoma. AIDS Patient Care STDS; 2007 Jul;21(7):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An uncommon presentation of HIV-related lymphoma.
  • Although highly active antiretroviral therapy has improved the clinical course of patients with HIV, this population remains at a significantly increased risk for non-Hodgkin's lymphoma (NHL).
  • We encountered a patient with HIV-related NHL who presented with a thoracic spinal cord compression and had a complicated clinical course as a result of the atypical presentation.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / complications. Lymphoma, Non-Hodgkin / virology. Spinal Cord Compression / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651024.001).
  • [ISSN] 1087-2914
  • [Journal-full-title] AIDS patient care and STDs
  • [ISO-abbreviation] AIDS Patient Care STDS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Levine AM: Management of AIDS-related lymphoma. Curr Opin Oncol; 2008 Sep;20(5):522-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of AIDS-related lymphoma.
  • PURPOSE OF REVIEW: With the advent of highly active antiretroviral therapy, the epidemiology of AIDS-lymphoma has changed, and prognosis has improved.
  • Although the incidence of AIDS-lymphoma has decreased, the incidence of HIV-associated Hodgkin's lymphoma has increased; mechanisms for these changes in epidemiology will be discussed.
  • RECENT FINDINGS: Use of highly active antiretroviral therapy, either concomitantly or immediately after completion of chemotherapy, has resulted in rates of complete remission and survival that are similar to those in HIV-negative patients.
  • The use of rituximab, while initially controversial because of reports of increased risk of infectious death, is associated with improved outcome; the increased risk of infectious death has not been confirmed.
  • The infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin regimen is associated with excellent results.
  • High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disease-free survival in approximately 50-80% of patients with relapsed/refractory AIDS-lymphoma.
  • Addition of rituximab is associated with improved response rates, without an increase in infections.
  • Infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is associated with excellent results among patients with either diffuse large B cell lymphoma or Burkitt's lymphoma.
  • Optimal therapy for patients with HIV-Hodgkin's lymphoma has not yet been defined.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106654.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


53. Goldstein MA, Naidich TP, Silverman ME: Clinical importance of delayed MRI contrast enhancement of primary central nervous system lymphoma in AIDS. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical importance of delayed MRI contrast enhancement of primary central nervous system lymphoma in AIDS.
  • Accurately distinguishing between cerebral toxoplasmosis and primary central nervous system lymphoma (PCNSL), still the most common secondary CNS mass lesion complications of AIDS, has long represented a diagnostic challenge in those with HIV.
  • A young adult male with AIDS presented with evolving ophthalmoplegias, Parinaud's syndrome and gait dysfunction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2003 Apr;24(4):554-5 [12695179.001]
  • [Cites] Neurology. 1998 Jan;50(1):21-6 [9443452.001]
  • (PMID = 21686485.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027744
  •  go-up   go-down


54. Rühl H, Bein G, Sachs UJ: Transfusion-associated graft-versus-host disease. Transfus Med Rev; 2009 Jan;23(1):62-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transfusion-associated graft-versus-host disease.
  • Transfusion-associated graft-versus-host disease (TA-GvHD) is a rare complication of blood transfusion that has a fatal outcome in most patients.
  • Among the potential risk factors that have been discussed to date, a definite hazard for developing TA-GvHD has been recognized for HLA-matched transfusions or transfusions from blood relatives, intrauterine and exchange transfusions, patients with congenital immunodeficiency syndromes, bone marrow transplantation, stem cell transplantation, or lymphomas.
  • Although postulated, an increased risk for term or preterm newborns and patients with HIV/AIDS has not thus far been demonstrated.
  • [MeSH-major] Blood Donors. Blood Transfusion. Graft vs Host Disease / diagnosis. Graft vs Host Disease / prevention & control. Graft vs Host Disease / therapy. HLA Antigens. T-Lymphocytes

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056035.001).
  • [ISSN] 1532-9496
  • [Journal-full-title] Transfusion medicine reviews
  • [ISO-abbreviation] Transfus Med Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Number-of-references] 137
  •  go-up   go-down


55. Pérez GR, Taborda MA, Toffi A, Palonsky M, Pagotto M, Gardiol DN, Giri AA: [Development of slides for Epstein-Barr virus diagnosis by indirect immunofluorescence]. Medicina (B Aires); 2005;65(4):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Desarrollo de improntas para el diagnóstico del virus Epstein-Barr por inmunofluorescencia indirecta.
  • Moreover, high titles of anti-VCA antibodies are observed in EBV-associated neoplasic disorders, such as lymphomas in AIDS patients.
  • In conclusion, the slides here presented can be a useful instrument for acute EBV infection diagnosis and for the serologic detection of IgG anti-VCA antibodies in EBV-associated neoplastic disorders.
  • [MeSH-minor] Adult. Antigens, Viral / analysis. Antigens, Viral / immunology. Burkitt Lymphoma / immunology. Capsid Proteins / analysis. Capsid Proteins / immunology. Equipment Design. Fluorescent Antibody Technique, Indirect. Humans. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193709.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Grant] United States / FIC NIH HHS / TW / 5 D43 TW001037
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Capsid Proteins; 0 / Epstein-Barr viral capsid antigen
  •  go-up   go-down


56. Dunleavy K, Wilson WH, Kaplan LD: The case for rituximab in AIDS-related lymphoma. Blood; 2006 Apr 1;107(7):3014-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The case for rituximab in AIDS-related lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Humans. Lymphoma, Non-Hodgkin / drug therapy. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • (PMID = 16554492.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


57. Du MQ, Bacon CM, Isaacson PG: Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol; 2007 Dec;60(12):1350-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders.
  • Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), is a recent addition to the list of human viruses that are directly associated with lymphoproliferative disorders.
  • KSHV was first shown to be involved in multicentric Castleman disease and primary effusion lymphoma (PEL).
  • Subsequently, the virus was identified in solid lymphomas, often of extranodal sites, with morphological and immunophenotypic characteristics similar to those of PEL, and in other lymphoproliferative disorders with heterogeneous clinicopathological presentations.
  • The recent advances in our understanding of the histology, immunophenotype and pathogenesis of these KSHV-associated lymphoproliferative disorders are reviewed.
  • [MeSH-minor] Cell Transformation, Neoplastic. Cell Transformation, Viral. Giant Lymph Node Hyperplasia / pathology. Giant Lymph Node Hyperplasia / virology. Humans. Lymphoma, Primary Effusion / pathology. Lymphoma, Primary Effusion / virology. Viral Proteins / physiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] J Virol. 2006 Jan;80(2):697-709 [16378973.001]
  • [Cites] Blood. 2006 Jan 15;107(2):725-32 [16160006.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3295-302 [16380446.001]
  • [Cites] Diagn Cytopathol. 2006 May;34(5):335-47 [16604559.001]
  • [Cites] J Exp Med. 2006 May 15;203(5):1295-305 [16682493.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:101-36 [17089795.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:157-83 [17089797.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):1019-28 [17364023.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):4979-86 [17310999.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1393-400 [10555008.001]
  • [Cites] Hum Immunol. 1999 Oct;60(10):921-7 [10566591.001]
  • [Cites] Eur Cytokine Netw. 1999 Dec;10(4):501-8 [10586116.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4247-54 [10590069.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):77-85 [10658913.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Leukemia. 2000 Feb;14(2):271-7 [10673744.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):743-9 [10702388.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1180-9 [10741750.001]
  • [Cites] J Clin Virol. 2000 May;16(3):215-24 [10738140.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1209-15 [10751346.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):729-36 [10793109.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2069-73 [10979949.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):247-57 [11091208.001]
  • [Cites] J Virol. 2001 Jan;75(1):429-38 [11119611.001]
  • [Cites] J Virol. 2001 Mar;75(6):2938-45 [11222719.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2130-6 [11264181.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2173-6 [11264189.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1093-9 [10400426.001]
  • [Cites] J Med Virol. 1999 Aug;58(4):394-401 [10421407.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2931-3 [10515899.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 1;156(1):49-53 [15588855.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):647-52 [15832089.001]
  • [Cites] Leukemia. 2005 May;19(5):851-5 [15744337.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Aug;100(2):198-206 [16037778.001]
  • [Cites] Mod Pathol. 2003 May;16(5):424-9 [12748248.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3371-85 [12776188.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):630 [12827623.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] Clin Transplant. 2003 Oct;17(5):451-4 [14703929.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):41-6 [14707862.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):581-9 [14744772.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):7643-54 [14668346.001]
  • [Cites] J Mol Med (Berl). 2004 Apr;82(4):223-31 [14991150.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):693-7 [15105661.001]
  • [Cites] Leuk Res. 2004 Apr;28(4):333-8 [15109530.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9399-404 [15190178.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1538-40; author reply 1540 [15489661.001]
  • [Cites] Semin Oncol. 1993 Dec;20(6):636-47 [8296200.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]
  • [Cites] AIDS. 1996 Jan;10(1):61-7 [8924253.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Leukemia. 1996 Aug;10(8):1358-62 [8709643.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] J Virol. 1997 Mar;71(3):1984-91 [9032330.001]
  • [Cites] Nat Med. 1997 Mar;3(3):287-92 [9055855.001]
  • [Cites] J Clin Pathol. 2005 Oct;58(10):1039-45 [16189148.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):123-7 [16330952.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2526-7 [11307774.001]
  • [Cites] Br J Haematol. 2001 May;113(2):425-8 [11380409.001]
  • [Cites] J Virol. 2001 Nov;75(22):10933-40 [11602733.001]
  • [Cites] Cell Immunol. 2001 Sep 15;212(2):118-25 [11748928.001]
  • [Cites] Blood. 2002 Jan 15;99(2):649-54 [11781250.001]
  • [Cites] Br J Haematol. 2002 Jan;116(1):113-21 [11841403.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13745-51 [11830587.001]
  • [Cites] AIDS Patient Care STDS. 2002 Apr;16(4):139-45 [12015867.001]
  • [Cites] Hum Pathol. 2002 Aug;33(8):846-9 [12203218.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):229-41 [12242155.001]
  • [Cites] J Infect Dis. 1997 May;175(5):1198-201 [9129085.001]
  • [Cites] J Virol. 1997 Jun;71(6):4193-8 [9151805.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1186-91 [9242551.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):788-97 [9264363.001]
  • [Cites] Immunol Rev. 1997 Apr;156:111-26 [9280752.001]
  • [Cites] Int J Cancer. 1997 Oct 9;73(2):303-4 [9335459.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4894-900 [9389706.001]
  • [Cites] Bull Acad Natl Med. 1997 Jun-Jul;181(6):1023-34 [9453829.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1858-63 [9490667.001]
  • [Cites] J Gen Virol. 1998 Jun;79 ( Pt 6):1445-52 [9634087.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1609-14 [9811353.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1528-37 [9850179.001]
  • [Cites] Lab Invest. 1998 Dec;78(12):1637-42 [9881964.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):16-23 [9892104.001]
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Leukemia. 1999 Apr;13(4):634-40 [10214873.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] J Exp Med. 2005 Aug 15;202(4):479-84 [16103407.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12885-90 [16120683.001]
  • (PMID = 18042691.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Viral Proteins
  • [Number-of-references] 114
  • [Other-IDs] NLM/ PMC2095558
  •  go-up   go-down


58. Mwakigonja AR, Kaaya EE, Heiden T, Wannhoff G, Castro J, Pak F, Porwit A, Biberfeld P: Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association. BMC Cancer; 2010;10:344
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association.
  • BACKGROUND: In Tanzania, the International Working Formulation [WF] rather than the WHO Classification is still being used in diagnosing malignant lymphomas (ML) and the biological characterization including the HIV/EBV association is sketchy, thus restraining comparison, prognostication and application of established therapeutic protocols.
  • METHODS: Archival, diagnostic ML biopsies (N = 336), available sera (N = 35) screened by ELISA for HIV antibodies and corresponding clinical/histological reports at Muhimbili National Hospital (MNH) in Tanzania between 1996 and 2006 were retrieved and evaluated.
  • RESULTS: A third (38.8%, 109/281) of the ML patients with available clinical information had extranodal disease presentation.
  • 8%, 134/158) non-Hodgkin lymphoma (NHL).
  • Most (83.6%, 112/134) of NHL were B-cell lymphomas (BCL) (CD20+), of which 50.9%, (57/112) were diffuse large B-cell (DLBCL).
  • Out of the 158 confirmed MLs, 22 (13.9%) were T-cell [CD3+] lymphomas (TCL) and 24 (15.2%) were Hodgkin lymphomas (HL) [CD30+].
  • The majority (51.4%, 19/37) of EBER ISH analyzed lymphoma biopsies were positive.
  • Of the serologically tested MLs, 40.0% (14/35) were HIV positive, mostly with high (> or =40.0%) Ki-67 reactivity.
  • Extranodal presentation was common among MNH lymphoma patients who also showed high aneuploidy, tumor proliferation (KI-67) and EBER positivity.
  • HIV was apparently associated with high ML cell proliferation but extended studies are needed to clarify this.
  • [MeSH-major] Cell Proliferation. Epstein-Barr Virus Infections / virology. HIV Infections / virology. Lymphoma, B-Cell / etiology. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / etiology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blotting, Western. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. HIV / pathogenicity. Herpesvirus 4, Human / pathogenicity. Humans. Immunoenzyme Techniques. In Situ Hybridization. Male. Middle Aged. Ploidies. Tanzania. World Health Organization. Young Adult


59. Verma N, Chaudhary UB, Costa LJ, Gudena V, Lazarchick J: Primary testicular lymphoma and AIDS. Ann Clin Lab Sci; 2010;40(1):75-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular lymphoma and AIDS.
  • Immunosuppressed patients have an increased risk for developing extranodal lymphoma, including testicular lymphoma.
  • In AIDS patients, primary testicular lymphoma has been reported as an initial manifestation of the disease.
  • These patients typically present at an early age; their lymphomas usually have aggressive histologic appearance and are associated with poor prognosis.
  • We report a testicular lymphoma consistent with diffuse large B-cell lymphoma (DLBCL) in an AIDS patient and we review the literature on primary testicular lymphoma in AIDS patients.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology


60. Zucchetto A, Bruzzone S, De Paoli A, Regine V, Pappagallo M, Dal Maso L, Serraino D, Rezza G, Suligoi B: [AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era]. Epidemiol Prev; 2009 Jul-Oct;33(4-5):184-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era].
  • [Transliterated title] AIDS e tossicodipendenza: determinanti della sopravvivenza nell'era delle terapie antiretrovirali altamente efficaci.
  • OBJECTIVES: to estimate survival, after AIDS diagnosis, in people who got infected with HIV through injecting drug use (IDUs), to identify among variables collected at AIDS diagnosis those which were associated to prognosis and to assess the frequency of morbid conditions at death.
  • SETTING AND PARTICIPANTS: 4,040 IDUs diagnosed with AIDS in Italy between 1999 and 2005.
  • RESULTS: the 2-year and 5-year survival probabilities after AIDS diagnosis of IDUs were 72% and 60%, respectively.
  • Elevated risks of death emerged for IDUs with older ages (HR=2.0 95% CI 1.6-2.4 for>45 years old vs.<35 years old), lower education (HR=1.4 95% CI 1.2-1.7 for elementary school vs. high school/university), longer time span between first HIV positive test and AIDS diagnosis (HR=1.6 95% CI 1.4-1.9 for > 6 months vs. < 6 months), and lower CD4 cell count at diagnosis (HR=1.5 95% CI 1.3-1.7 for <50 cells/mm3 vs. > 200 cells/mm3).
  • Compared to Pneumocystis carinii pneumonia, non-Hodgkin lymphomas were the worst prognostic factors, particularly primary brain lymphoma (HR=7.2, 95% CI 4.4-11.8).
  • 52% of cases reported no AIDS-defining illnesses: 64 (4%) violent causes, 94 (6%) cancers, and 656 (42%) only non neoplastic illnesses, among which 415 (27%) liver diseases.
  • CONCLUSION: the results of this population-based study showed that, in the highly active antiretroviral therapy era, survival of IDUs with AIDS was still lower compared to that of HIV sexual transmission groups.
  • The presence at death, in 52% of cases, of non AIDS-defining illnesses indicates the important role on mortality of co-morbidities, including liver diseases and violent causes.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / mortality. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Substance Abuse, Intravenous / epidemiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / mortality. Age Factors. Comorbidity. Death Certificates. Educational Status. Equipment Contamination. HIV Infections / transmission. Homicide / statistics & numerical data. Humans. Italy / epidemiology. Kaplan-Meier Estimate. Liver Diseases / mortality. Lymphoma, AIDS-Related / mortality. Medical Record Linkage. Needles. Proportional Hazards Models. Registries. Retrospective Studies. Risk. Sexual Behavior


61. Bedoya F, Medveczky MM, Lund TC, Perl A, Horvath J, Jett SD, Medveczky PG: Identification of mitochondrial genome concatemers in AIDS-associated lymphomas and lymphoid cell lines. Leuk Res; 2009 Nov;33(11):1499-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of mitochondrial genome concatemers in AIDS-associated lymphomas and lymphoid cell lines.
  • Since most oncogenic viruses persist as extrachromosomal covalently closed circular DNA (cccDNA) in tumor cells, we developed an assay to visualize and identify cccDNA in primary lymphomas.
  • One AIDS-associated lymphoma (EL) was further studied in detail as its mitochondrial genome consisted of tandem head-to-tail duplications.
  • Insertion of C-residues was noted near the origin of replication of EL mtDNA.
  • EL cells responded weakly to Fas-apoptotic stimulus, displayed reduced mitochondrial activity and mass, and produced higher levels of reactive oxygen intermediates.
  • Screening of several AIDS-associated lymphomas and established lymphoid cell lines also revealed the presence of mitochondrial genome concatemers consisting of interlinked monomer molecules.
  • Taken together, our results suggest that formation of mtDNA concatemers is associated with oncogenic transformation in lymphoid cells.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14453-8 [18796602.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7015-9 [11585726.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(3):145-55 [12621474.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] IUBMB Life. 2003 Apr-May;55(4-5):213-7 [12880201.001]
  • [Cites] Mol Genet Genomics. 2003 Jul;269(4):454-63 [12768414.001]
  • [Cites] Science. 2004 May 14;304(5673):981 [15143273.001]
  • [Cites] Biopolymers. 1970;9(3):373-9 [5417647.001]
  • [Cites] J Virol. 1984 Apr;50(1):248-54 [6321792.001]
  • [Cites] J Virol. 1989 Sep;63(9):3601-11 [2547988.001]
  • [Cites] Antimicrob Agents Chemother. 1994 Dec;38(12):2743-9 [7695256.001]
  • [Cites] Nucleic Acids Res. 1996 Oct 15;24(20):4084-91 [8918816.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1172-6 [9037025.001]
  • [Cites] Nature. 1997 Apr 3;386(6624):517-21 [9087414.001]
  • [Cites] Nucleic Acids Res. 1998 Feb 15;26(4):967-73 [9461455.001]
  • [Cites] Biochem Z. 1962;336:281-98 [14003030.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24 [15647368.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Biochim Biophys Acta. 2006 May-Jun;1757(5-6):700-7 [16782042.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:363-74 [16869773.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4647-62 [16892079.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] J Infect Dis. 2007 May 15;195(10):1419-25 [17436221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):9001-6 [17517629.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4331-5 [17671113.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Methods Mol Biol. 2007;372:153-66 [18314724.001]
  • [Cites] Cancer Lett. 2008 Jul 18;266(1):30-6 [18372105.001]
  • [Cites] Cancer Lett. 2008 Jul 18;266(1):21-9 [18374479.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):789-95 [11048730.001]
  • (PMID = 19362738.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA111196-04; United States / NCI NIH HHS / CA / CA111196-02; United States / NCI NIH HHS / CA / R01CA111196; United States / NCI NIH HHS / CA / R01 CA111196-01A2; United States / NCI NIH HHS / CA / CA111196-03; United States / NCI NIH HHS / CA / R01 CA111196-03; United States / NCI NIH HHS / CA / CA111196-04; United States / NCI NIH HHS / CA / R01 CA111196; United States / NCI NIH HHS / CA / R01 CA111196-02; United States / NCI NIH HHS / CA / CA111196-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Mitochondrial
  • [Other-IDs] NLM/ NIHMS103972; NLM/ PMC2730422
  •  go-up   go-down


62. Gao L, Deng H, Zhao H, Hirbe A, Harding J, Ratner L, Weilbaecher K: HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood; 2005 Dec 15;106(13):4294-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One in 20 carriers of human T-cell leukemia virus type 1 (HTLV-1) will develop adult T-cell leukemia/lymphoma (ATL), a disease frequently associated with hypercalcemia, bone destruction, and a fatal course refractory to current therapies.
  • Overexpression of the HTLV-1-encoded Tax oncoprotein under the human granzyme B promoter causes large granular lymphocytic leukemia/lymphomas in mice.
  • Mice doubly transgenic for Tax and the osteoclast inhibitory factor, osteoprotegerin, were protected from osteolytic bone disease and developed fewer soft-tissue tumors.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1997 Apr 18;89(2):309-19 [9108485.001]
  • [Cites] Annu Rev Immunol. 1997;15:15-37 [9143680.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1557-63 [9362422.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):593-602 [9469347.001]
  • [Cites] Methods. 1998 Sep;16(1):83-94 [9774518.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:919-30 [15569630.001]
  • [Cites] J Bone Miner Res. 2005 Jan;20(1):58-66 [15619670.001]
  • [Cites] Skeletal Radiol. 1985;14(3):194-7 [2997937.001]
  • [Cites] J Clin Invest. 1987 Sep;80(3):911-6 [2887587.001]
  • [Cites] J Clin Invest. 1999 Jan;103(2):197-206 [9916131.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3305-11 [15292059.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):185-95 [15324701.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2852-9 [15353320.001]
  • [Cites] Calcif Tissue Int. 2004 Jul;75(1):71-7 [15037971.001]
  • [Cites] Am J Pathol. 1988 Sep;132(3):593-7 [3414786.001]
  • [Cites] J Bone Miner Res. 1987 Dec;2(6):595-610 [3455637.001]
  • [Cites] Cancer Res. 1988 Dec 1;48(23):6876-81 [3180096.001]
  • [Cites] Endocrinology. 1989 Oct;125(4):1805-13 [2676473.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1989 Nov-Dec;83(6):729-31 [2617642.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):759-65 [2388034.001]
  • [Cites] Blood. 1991 Jun 1;77(11):2451-5 [2039827.001]
  • [Cites] Science. 1991 Aug 30;253(5023):1026-8 [1887217.001]
  • [Cites] J Virol. 1991 Oct;65(10):5471-6 [1895396.001]
  • [Cites] Virology. 1993 Nov;197(1):196-204 [8212554.001]
  • [Cites] Blood. 1994 Nov 1;84(9):2904-11 [7949164.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [7862633.001]
  • [Cites] Baillieres Clin Haematol. 1995 Mar;8(1):131-48 [7663044.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S162-9 [8797719.001]
  • [Cites] J Clin Invest. 1996 Oct 1;98(7):1544-9 [8833902.001]
  • [Cites] Oncogene. 2005 Jan 20;24(4):525-40 [15580311.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1129-35 [15734993.001]
  • [Cites] Leukemia. 2005 Apr;19(4):664-70 [15744346.001]
  • [Cites] Retrovirology. 2004;1:20 [15310405.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1082-90 [10699899.001]
  • [Cites] Blood. 2000 Jul 1;96(1):275-81 [10891462.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2961-78 [10898340.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2979-88 [10898341.001]
  • [Cites] J Virol. 2000 Dec;74(23):11394-7 [11070040.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1677-81 [11080809.001]
  • [Cites] J Clin Invest. 2000 Dec;106(12):1481-8 [11120755.001]
  • [Cites] J Virol. 2001 Mar;75(5):2185-93 [11160722.001]
  • [Cites] Blood. 2002 Jan 1;99(1):88-94 [11756157.001]
  • [Cites] Blood. 2002 Jan 15;99(2):634-40 [11781248.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 18;290(2):650-5 [11785948.001]
  • [Cites] Leuk Res. 2002 Jun;26(6):561-7 [12007504.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3219-24 [12149294.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):584-93 [12154351.001]
  • [Cites] J Dermatol. 2002 Oct;29(10):644-7 [12432996.001]
  • [Cites] J Clin Invest. 2002 Nov;110(10):1559-72 [12438453.001]
  • [Cites] J Exp Med. 2003 Jan 20;197(2):163-8 [12538656.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):748-57 [12548572.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 21):19-27 [12584691.001]
  • [Cites] Curr Rheumatol Rep. 2003 Feb;5(1):65-74 [12590887.001]
  • [Cites] J Bone Miner Res. 2003 Mar;18(3):482-92 [12619933.001]
  • [Cites] Blood. 2003 Jul 1;102(1):200-6 [12623838.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9506-11 [12881486.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(3):204-11 [12970722.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1468-76 [14504045.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6170-3 [14559799.001]
  • [Cites] Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S19-31 [14600589.001]
  • [Cites] Breast. 2003 Aug;12 Suppl 2:S22-9 [14659140.001]
  • [Cites] J Bone Miner Res. 2004 Feb;19(2):278-88 [14969398.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1655-64 [15084698.001]
  • [Cites] J Bone Miner Res. 2004 Jul;19(7):1105-11 [15176993.001]
  • [Cites] Blood. 2004 Aug 1;104(3):802-9 [15090453.001]
  • [Cites] Br J Haematol. 2004 Aug;126(4):583-92 [15287953.001]
  • [Cites] Jpn J Cancer Res. 1996 Sep;87(9):887-92 [8878449.001]
  • [Cites] N Engl J Med. 1996 Dec 12;335(24):1785-91 [8965890.001]
  • [Cites] J Natl Cancer Inst. 1996 Nov 20;88(22):1652-8 [8931609.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14(3):272-80 [9117461.001]
  • (PMID = 16118323.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100730; United States / NIDDK NIH HHS / DK / P30 DK056341; United States / NCI NIH HHS / CA / P30 CA91842; United States / NCI NIH HHS / CA / P30 CA091842; United States / NIDDK NIH HHS / DK / DK56341
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Interleukin-6; 0 / Lymphokines; 0 / Organophosphonates; 64060-24-8 / osteoclast activating factor
  • [Other-IDs] NLM/ PMC1895233
  •  go-up   go-down


63. Tschudin S, Sponagel L, Flückiger U: [Dangerous fever]. Ther Umsch; 2006 Oct;63(10):651-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additionally, fever is a frequent symptom in non-infectious diseases, e.g. autoimmune diseases or lymphomas.
  • The term dangerous fever describes febrile conditions which are associated with high mortality and, in most cases, mandate hospitalization, and even monitoring in an intensive care unit.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / diagnosis. Adult. Bacterial Infections / diagnosis. Diagnosis, Differential. Humans. Male. Opportunistic Infections / diagnosis. Prognosis. Shock, Septic / diagnosis. Systemic Inflammatory Response Syndrome / diagnosis

  • MedlinePlus Health Information. consumer health - Critical Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17048184.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


64. Castillo J, Hansen C, Mega A, Tashima K: AIDS-related lymphomas: the Rhode Island experience. Med Health R I; 2008 Nov;91(11):332-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas: the Rhode Island experience.
  • [MeSH-major] Lymphoma, AIDS-Related

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19093379.001).
  • [ISSN] 1086-5462
  • [Journal-full-title] Medicine and health, Rhode Island
  • [ISO-abbreviation] Med Health R I
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, Falk PM, Rosenthal J, Alvarnas J, Forman SJ: Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood; 2005 Jan 15;105(2):874-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas.
  • The treatment of HIV-associated lymphoma has changed since the widespread use of highly active antiretroviral therapy.
  • HIV-infected individuals can tolerate more intensive chemotherapy, as they have better hematologic reserves and fewer infections.
  • This has led to higher response rates in patients with HIV-associated Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) treated with chemotherapy in conjunction with antiretroviral therapy.
  • However, for patients with refractory or relapsed disease, salvage chemotherapy still offers little chance of long-term survival.
  • In the non-HIV setting, patients with relapsed Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) have a better chance of long-term remission with high-dose chemotherapy with autologous stem cell rescue (ASCT) compared with conventional salvage chemotherapy.
  • In a prior report we demonstrated that this approach is well tolerated in patients with underlying immunodeficiency from HIV infection.
  • Furthermore, similar engraftment to the non-HIV setting and low infectious risks have been observed.
  • With long-term follow-up we demonstrate that ASCT can lead to an 85% progression-free survival, which suggests that this approach may be potentially curative in select patients with relapsed HIV-associated HD or NHL.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. CD4 Lymphocyte Count. Child. Disease-Free Survival. Follow-Up Studies. Humans. Middle Aged. Recurrence. Remission Induction. Risk Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15388574.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI38592; United States / NCI NIH HHS / CA / CA30206; United States / NCI NIH HHS / CA / CA33572
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


66. Dayyani F, Pantanowitz L, Sandridge TG, Sullivan RJ, Dezube BJ: Multicentric Castleman's disease masquerading as HIV-related lymphoma. Am J Med Sci; 2007 Oct;334(4):317-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric Castleman's disease masquerading as HIV-related lymphoma.
  • Patients with human immunodeficiency virus (HIV) infection are at increased risk for developing lymphoproliferative disorders.
  • Multicentric Castleman's disease should always be kept in the differential diagnosis of HIV-positive patients suspected of having lymphoma to avoid misdiagnosis.
  • We report the case of a 40-year-old HIV-positive homosexual man who presented with lower back pain and features highly suggestive of lymphoma including lymphadenopathy, elevated lactic dehydrogenase, and splenomegaly.
  • The patient's plasma was positive by polymerase chain reaction for Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/ HHV8), and a lymph node biopsy revealed Multicentric Castleman's disease.
  • Albeit a rare condition, Castleman's disease should always be considered in immunocompromised patients suspected of having lymphoma.
  • [MeSH-major] Giant Lymph Node Hyperplasia / diagnosis. Lymphoma, AIDS-Related / diagnosis


67. Qin Z, Kearney P, Plaisance K, Parsons CH: Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. J Leukoc Biol; 2010 Jan;87(1):25-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes.
  • KSHV is the causative agent of KS and lymphomas preferentially arising in immuno compromised patients, and specific cytokines, including IL-6 and IL-10, have been implicated in KSHV-associated cancer pathogenesis.
  • However, the contribution of KSHV-infected macrophages to the cytokine milieu within KSHV-related tumors is unclear.
  • In addition,RNA interference specifically targeting LIP induced basal secretion of IL-6 and IL-10 by macrophages.Taken together, these data support a role for KSHV miRNA in the programming of macrophage cytokine responses in favor of KSHV-related tumor progression.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1998 Feb 1;91(3):968-76 [9446658.001]
  • [Cites] Annu Rev Immunol. 2001;19:683-765 [11244051.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2069-73 [10979949.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Leukemia. 1999 Apr;13(4):634-40 [10214873.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] J Invest Dermatol. 2004 Dec;123(6):1169-75 [15610530.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5 [15800047.001]
  • [Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]
  • [Cites] Clin Exp Allergy. 2005 Jun;35(6):782-9 [15969670.001]
  • [Cites] AIDS. 2005 Jul 22;19(11):1229-31 [15990578.001]
  • [Cites] J Virol. 2005 Jul;79(14):9301-5 [15994824.001]
  • [Cites] Mol Cell. 2005 Oct 7;20(1):3-7 [16209940.001]
  • [Cites] AIDS. 2005 Nov 4;19(16):1907-10 [16227799.001]
  • [Cites] J Immunol. 2001 Apr 1;166(7):4312-8 [11254683.001]
  • [Cites] J Virol. 2002 May;76(10):4688-98 [11967286.001]
  • [Cites] Biochem J. 2002 Aug 1;365(Pt 3):561-75 [12006103.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10683-8 [12145325.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]
  • [Cites] Cytokine. 2003 Mar 7;21(5):242-7 [12824009.001]
  • [Cites] J Immunol. 2003 Jul 15;171(2):821-8 [12847250.001]
  • [Cites] J Virol. 2003 Aug;77(16):8893-914 [12885907.001]
  • [Cites] J Biomed Sci. 2004 Jul-Aug;11(4):517-27 [15153787.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Science. 1989 Nov 17;246(4932):911-6 [2683088.001]
  • [Cites] Cell. 1991 Nov 1;67(3):569-79 [1934061.001]
  • [Cites] Adv Immunol. 1994;56:1-26 [8073945.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] J Virol. 1997 Oct;71(10):7963-8 [9311888.001]
  • [Cites] Ann Diagn Pathol. 1999 Dec;3(6):357-63 [10594287.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10794-800 [16322225.001]
  • [Cites] Nat Immunol. 2006 Feb;7(2):131-7 [16424890.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1963-73 [16794734.001]
  • [Cites] Cell Signal. 2006 Nov;18(11):1865-75 [16600570.001]
  • [Cites] J Virol. 2006 Nov;80(21):10874-8 [16956953.001]
  • [Cites] J Virol. 2006 Dec;80(24):12171-86 [17020951.001]
  • [Cites] J Leukoc Biol. 2007 Jan;81(1):221-8 [17023556.001]
  • [Cites] J Interferon Cytokine Res. 2006 Dec;26(12):893-900 [17238832.001]
  • [Cites] J Infect Dis. 2007 Mar 1;195(5):645-59 [17262705.001]
  • [Cites] J Biochem. 2007 Feb;141(2):137-45 [17190786.001]
  • [Cites] J Virol. 2007 May;81(10):5079-90 [17329329.001]
  • [Cites] PLoS Pathog. 2007 May 11;3(5):e65 [17500590.001]
  • [Cites] Immunol Cell Biol. 2007 Aug-Sep;85(6):420-4 [17637696.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2685-95 [17525287.001]
  • [Cites] Eur J Immunol. 2007 Oct;37(10):2900-11 [17899538.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):272-86 [18328430.001]
  • [Cites] J Biol Chem. 2008 Mar 14;283(11):6843-53 [18195020.001]
  • [Cites] J Immunol. 2008 Apr 15;180(8):5689-98 [18390754.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Virol. 2008 Jun;82(11):5440-9 [18367536.001]
  • [Cites] Immunol Lett. 2008 Oct 30;120(1-2):37-41 [18680763.001]
  • [Cites] Cytokine. 2008 Sep;43(3):391-4 [18701320.001]
  • [Cites] Cell Host Microbe. 2008 Nov 13;4(5):470-83 [18996347.001]
  • [Cites] J Immunol. 2009 Feb 15;182(4):2258-68 [19201880.001]
  • [Cites] J Cell Physiol. 2009 Jun;219(3):698-706 [19229882.001]
  • [CommentIn] J Leukoc Biol. 2010 Jan;87(1):9-12 [20047884.001]
  • (PMID = 20052801.001).
  • [ISSN] 1938-3673
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA142362; United States / NCRR NIH HHS / RR / P20-RR-017696; United States / NCI NIH HHS / CA / K08 CA103858-05; United States / NCI NIH HHS / CA / CA103858-05; United States / NCRR NIH HHS / RR / P20 RR017696-085957; United States / NCI NIH HHS / CA / P30 CA138313; United States / NCI NIH HHS / CA / K08-1CA103858; United States / NCRR NIH HHS / RR / RR017696-085957; United States / NCI NIH HHS / CA / K08 CA103858; United States / NCRR NIH HHS / RR / P20 RR017696; United States / NCI NIH HHS / CA / P30-CA-138313
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / CCAAT-Enhancer-Binding Protein-beta; 0 / IL10 protein, human; 0 / IL6 protein, human; 0 / Interleukin-6; 0 / MicroRNAs; 0 / Protein Isoforms; 0 / RNA, Viral; 130068-27-8 / Interleukin-10
  • [Other-IDs] NLM/ PMC2801620
  •  go-up   go-down


68. Das DK: Serous effusions in malignant lymphomas: a review. Diagn Cytopathol; 2006 May;34(5):335-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous effusions in malignant lymphomas: a review.
  • Serous effusions are a common complication of lymphomas.
  • Although the frequency of pleural effusion is 20-30% in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD), the involvement of peritoneal and pericardial cavities is uncommon.
  • Among lymphoma subtypes, T-cell neoplasms, especially the lymphoblastic lymphomas, more frequently involve the serous fluids.
  • Cytologic features of specific lymphoma subtypes such as lymphoblastic lymphoma, follicular center cell lymphoma, including Burkitt-type lymphoma, marginal zone lymphoma, MALT lymphoma, and anaplastic large-cell lymphoma, etc., have been described in the literature.
  • The differential diagnostic problems of lymphomas in serous effusions include reactive lymphocytoses, early involvement by lymphomatous process, small round-cell tumors (SRCT), and presence of look-alike of Reed-Sternberg cells.
  • ICC not only distinguishes lymphomas from reactive lymphocytoses and SRCTs, it significantly modifies the morphologic diagnosis to achieve a better classification of lymphomas.
  • Morphometry also distinguishes reactive lymphocytoses from malignant lymphoma with a high degree of sensitivity (>85%) and specificity (>95%).
  • Although lymphomas rarely present as serous effusions without the involvement of other thoracic and extrathoracic sites, a small group of lymphomas called primary effusion lymphomas (PEL) exhibit exclusive or dominant involvement of serous cavities, without a detectable solid tumor mass.
  • This body cavity based lymphoma (BCBL) is a distinct clinicopathologic entity and is found predominantly in AIDS patients with preexisting Kaposi sarcoma.
  • Cytomorphologically, PEL is usually a large-cell lymphoma, which appears to bridge features of large-cell immunoblastic and anaplastic large-cell lymphoma (ALCL).
  • Most of these cases comprise a unique subgroup of B-cell lymphoma, with features of both high-grade anaplastic and B-immunoblastic lymphoma, but T-cell and/or natural killer cell immunophenotypes are described.
  • Pleural effusion due to lymphomas, either primary or otherwise, is considered as one of the factors adversely influencing overall survival.
  • The presence of pleural effusion at the time of presentation is not only associated with extremely poor outcome of lymphomas, it is also a predictor of disease relapse after chemotherapy and decreased survival.
  • In such situations, cytology along with ancillary studies not only gives a quick diagnosis of lymphoma, but also offers prognostically significant information such as classification of lymphomas, its grade and immunophenotype, and presence/absence of viral DNAs and tumor lysis syndrome.
  • [MeSH-major] Cytodiagnosis / methods. Lymphoma / complications. Pleural Effusion, Malignant / etiology
  • [MeSH-minor] Ascitic Fluid / pathology. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Female. Hodgkin Disease / pathology. Humans. Immunophenotyping. Lymphocytosis / pathology. Male. Pericardial Effusion / etiology. Pericardial Effusion / pathology. Reed-Sternberg Cells / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604559.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 136
  •  go-up   go-down


69. Wolf T, Brodt HR, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm EB, Mitrou PS, Chow KU: Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma; 2005 Feb;46(2):207-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).
  • Non-Hodgkin's lymphoma is an AIDS-defining disease.
  • We collected data of 214 cases of AIDS-related Lymphoma (ARL) treated at our centre from January 1984 until May 2003 and analysed them using the Kaplan-Meier-, log rank- and Cox proportional hazard-model.
  • The incidence of AIDS-related primary CNS lymphomas (PCNSL) took a comparable, yet more pronounced development.
  • Using the univariate Kaplan-Meier analysis prolonged survival was significantly associated with the achievement of a complete remission as well as with a favourable virological response to HAART.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621803.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


70. Camilleri-Broët S, Raphaël M: [Physiopathogenic aspects of HIV-associated primary brain lymphomas]. Rev Neurol (Paris); 2006 Jan;162(1):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Physiopathogenic aspects of HIV-associated primary brain lymphomas].
  • [Transliterated title] Les lymphomes cérébraux primitifs associés au SIDA: aspects physiopathogéniques.
  • HIV-associated Primary brain lymphomas (PBLs) are usually diffuse, large B-cell lymphomas (DLBCLs).
  • In contrast to those occurring in immunocompetent patients, nearly all HIV-associated PBLs are associated with Epstein-Barr virus (EBV).
  • Since viral latency proteins are target antigens for anti-viral cytotoxic T lymphocytes, the double immunodeficiency (HIV infection, central nervous system microenvironment) favors the expression of viral latency proteins (LMP-1, EBNA2).
  • [MeSH-major] Brain Neoplasms / physiopathology. Lymphoma, AIDS-Related / physiopathology
  • [MeSH-minor] B-Lymphocytes / pathology. B-Lymphocytes / virology. Biopsy. Brain / pathology. Brain / virology. Cerebrospinal Fluid / immunology. Epstein-Barr Virus Infections / complications. HIV / physiology. Herpesvirus 4, Human / isolation & purification. Humans. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / physiopathology. Lymphoma, Large B-Cell, Diffuse / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446623.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 25
  •  go-up   go-down


71. Riedel DJ, Gonzalez-Cuyar LF, Zhao XF, Redfield RR, Gilliam BL: Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis; 2008 Apr;8(4):261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection.
  • Plasmablastic lymphoma of the oral cavity is a form of non-Hodgkin lymphoma (NHL) and was first described in 1997.
  • We describe a case of plasmablastic lymphoma in an HIV-infected patient who presented with an expanding oral lesion and symptoms of a toothache.
  • We review all cases of plasmablastic lymphoma that have been reported in the literature.
  • Plasmablastic lymphoma is strongly associated with immunodeficiency, and most particularly, with HIV infection.
  • The pathophysiological origin of plasmablastic lymphoma has not been fully characterised, but the presence of Epstein-Barr virus (EBV) has often been documented in biopsy specimens, supporting a role for EBV in the pathogenesis of this lymphoma.
  • Infectious disease clinicians should be aware of this newly described and increasingly encountered lymphoma, since it is prominently associated with immunosuppression and may be mistaken for other entities.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Mouth / pathology. Mouth Neoplasms / diagnosis
  • [MeSH-minor] Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Head / radiography. Humans. Male. Tomography, X-Ray Computed. Toothache / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Lancet Infect Dis. 2010 Apr;10(4):226
  • (PMID = 18353267.001).
  • [ISSN] 1473-3099
  • [Journal-full-title] The Lancet. Infectious diseases
  • [ISO-abbreviation] Lancet Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


72. Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, Spina M, Manuele R, Vaccher E, Mazzucato M, Abbruzzese L, Ferremi P, Carosi G, Tirelli U, Rossi G: High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood; 2009 Aug 13;114(7):1306-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors.
  • After the introduction of highly active antiretroviral therapy (HAART), intensive treatment, including high-dose therapy (HDT) and peripheral blood stem cell transplantation (PBSCT), has become feasible in HIV-positive patients with Hodgkin (HL) and non-Hodgkin (NHL) lymphoma.
  • Herein, we report the long-term results, on an intention-to-treat basis, of a prospective study on HDT and PBSCT in 50 HIV-positive HAART-responding patients with refractory/relapsed lymphoma.
  • After debulking therapy, 2 patients had early toxic deaths, 10 had chemoresistant disease, 6 failed stem cell mobilization, 1 refused collection, and 4 progressed soon after PBSC harvest.
  • Twenty-one patients are alive and disease-free after a median follow-up of 44 months (OS, 74.6%; PFS, 75.9%).
  • Only lymphoma response significantly affected OS after transplantation.
  • In multivariate analyses both lymphoma stage and low CD4 count negatively influenced the possibility to receive transplant.
  • PBSCT is a highly effective salvage treatment for chemosensitive AIDS-related lymphoma.
  • It seems rational to explore its use earlier during the course of lymphoma to increase the proportion of patients who can actually receive transplant.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / therapy. Antiretroviral Therapy, Highly Active. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. CD4 Lymphocyte Count. Disease-Free Survival. Female. Follow-Up Studies. Humans. Italy. Male. Middle Aged. Salvage Therapy / methods. Survival Rate. Transplantation, Autologous


73. Martí-Carvajal AJ, Cardona AF, Lawrence A: Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma. Cochrane Database Syst Rev; 2009;(3):CD005419
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma.
  • BACKGROUND: Human immunodeficiency virus (HIV) infection is known to be associated with an increased risk of non-Hodgkin's lymphoma (NHL).
  • The majority of lymphomas (>80%) occurring during immunosuppression are aggressive B-cell in origin and have a high-to-intermediate histology grade.
  • OBJECTIVES: To assess the clinical effectiveness and safety of single agent or combination chemotherapy with or without immunochemotherapy (rituximab) and with or without highly active antiretroviral therapy (HAART) on overall survival (OS) and disease-free survival (DFS) for previously untreated patients with AIDS-related NHL.
  • For additional information see the Cochrane HIV/AIDS Group search strategy.
  • SELECTION CRITERIA: Randomized controlled trials (RCTs) assessing the effectiveness of systemic treatments for previously untreated AIDS-related NHL.
  • Disease free survival (DFS) was reported in two of the four RCTs, but it was not statistically significant between treatment groups.
  • AUTHORS' CONCLUSIONS: We found no evidence that the systemic interventions for untreated patients with AIDS-related NHL provide superior clinical effectiveness for improving OS, DSF, and tumour response rate; however, this conclusion is based on four RCTs with limited sample size and variable quality.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antiretroviral Therapy, Highly Active. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Prednisolone / administration & dosage. Prednisone / administration & dosage. Randomized Controlled Trials as Topic. Rituximab. Vincristine / administration & dosage. Vindesine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19588373.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q573I9DVLP / Leucovorin; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; LNH 87 protocol; M-BACOD protocol; VAP-cyclo protocol
  • [Number-of-references] 112
  •  go-up   go-down


74. Díez-Martín JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, Conde E, Rosselet A, Gabriel I, Varela R, Allione B, Cwynarski K, Genet P, Espigado I, Biron P, Schmitz N, Hunter AE, Ferrant A, Guillerm G, Hentrich M, Jurado M, Fernández P, Serrano D, Rossi G, Sureda A, European Group for Blood and Marrow Transplantation Lymphoma Working Party: Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood; 2009 Jun 4;113(23):6011-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation.
  • Autologous stem cell transplantation (ASCT) has been successfully used in HIV-related lymphoma (HIV-Ly) patients on highly active antiretroviral therapy.
  • We report the first comparative analysis between HIV-Ly and a matched cohort of HIV(-) lymphoma patients.
  • This retrospective European Group for Blood and Marrow Transplantation study included 53 patients (66% non-Hodgkin and 34% Hodgkin lymphoma) within each cohort.
  • Both groups were comparable except for the higher proportion of males, mixed-cellularity Hodgkin lymphoma and patients receiving granulocyte colony-stimulating factor before engraftment and a smaller proportion receiving total body irradiation-based conditioning within the HIV-Ly cohort.
  • A higher nonrelapse mortality within the first year after ASCT was observed in the HIV-Ly group (8% vs 2%), predominantly because of early bacterial infections, although this was not statistically significant and did not influence survival.
  • Thus, within the highly active antiretroviral therapy era, HIV patients should be considered for ASCT according to the same criteria adopted for HIV(-) lymphoma patients.
  • [MeSH-major] HIV Infections / surgery. Hodgkin Disease / surgery. Peripheral Blood Stem Cell Transplantation


75. Lankes HA, Fought AJ, Evens AM, Weisenburger DD, Chiu BC: Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study. Cancer Causes Control; 2009 Jul;20(5):517-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study.
  • OBJECTIVE: As factors that alter the immune system have been implicated in non-Hodgkin lymphoma (NHL) etiology, it is of interest to explore the association between vaccination and risk of NHL.
  • RESULTS: We found that NHL risk was inversely associated with ever receiving a polio (OR = 0.59, CI = 0.40-0.87) or smallpox (OR = 0.71, CI = 0.51-0.98) vaccination, and positively associated with influenza vaccination (OR = 1.53, CI = 1.14-2.06).
  • Analysis by histologic subtypes showed that polio vaccination was associated with a lower risk of follicular (OR = 0.54, CI = 0.31-0.92) and chronic lymphocytic leukemia/small lymphocytic lymphomas (OR = 0.29, CI = 0.12-0.69) and smallpox vaccination was associated with a lower risk of marginal zone lymphoma (OR = 0.41, CI = 0.19-0.88).
  • In contrast, ever receiving an influenza vaccination was associated with a higher risk of follicular (OR = 1.98, CI = 1.23-3.18) and diffuse large B cell lymphomas (OR = 1.88, CI = 1.13-3.12).
  • CONCLUSION: Risk of NHL is inversely associated with polio and smallpox vaccination and positively associated with influenza vaccination.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Vaccination / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Immunization.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2000 Feb;9(1):59-64 [10777011.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Science. 2002 Apr 19;296(5567):490-4 [11964470.001]
  • [Cites] Vaccine. 2003 Jan 17;21(5-6):419-30 [12531640.001]
  • [Cites] Am J Epidemiol. 2003 Aug 15;158(4):316-27 [12915497.001]
  • [Cites] Clin Lymphoma. 2003 Dec;4(3):161-8 [14715098.001]
  • [Cites] Eur J Haematol. 2004 May;72(5):336-41 [15059068.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):571-3 [15100327.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5465s-5467s [1327508.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5510s-5515s [1394165.001]
  • [Cites] Am J Epidemiol. 1993 Dec 1;138(11):923-36 [8256780.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3047-53 [7949176.001]
  • [Cites] Am J Prev Med. 1999 Apr;16(3):173-7 [10198654.001]
  • [Cites] Am J Epidemiol. 1999 Aug 15;150(4):375-89 [10453814.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):133-42 [15617998.001]
  • [Cites] Vaccine. 2005 Jan 11;23(8):1015-20 [15620474.001]
  • [Cites] Br J Haematol. 2005 Mar;128(5):610-5 [15725081.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3034-44 [16397126.001]
  • [Cites] Acta Oncol. 2006;45(3):258-71 [16644568.001]
  • [Cites] Immunity. 2006 Jun;24(6):663-6 [16782020.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):417-24 [16894287.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8 [17337643.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]
  • [Cites] Vaccine. 2007 Jun 15;25(25):4775-83 [17499402.001]
  • [Cites] Cancer Causes Control. 2007 Aug;18(6):677-85 [17484069.001]
  • [Cites] Cancer Causes Control. 2007 Oct;18(8):821-31 [17588155.001]
  • [Cites] Immunity. 2007 Nov;27(5):687-90 [18031690.001]
  • (PMID = 19011978.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA109613; United States / NCI NIH HHS / CA / R25 CA100600; United States / NCI NIH HHS / CA / R25 CA100600
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS399830; NLM/ PMC3446202
  •  go-up   go-down


76. Pagès F, Galon J, Karaschuk G, Dudziak D, Camus M, Lazar V, Camilleri-Broët S, Lagorce-Pagès C, Lebel-Binay S, Laux G, Fridman WH, Henglein B: Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood; 2005 Feb 15;105(4):1632-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show here that the EBV nuclear antigen EBNA2 induces expression of the 2 chains of the interleukin-18 receptor (IL-18R) in Burkitt lymphoma (BL) cell lines and in nontransformed B cells.
  • We report that EBNA2 expression is associated with IL-18R expression in vivo in EBV-positive B-lymphomas from AIDS patients.
  • [MeSH-minor] Burkitt Lymphoma / immunology. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / virology. Cell Line, Transformed. Cell Line, Tumor. Gene Expression Regulation, Viral / immunology. Genes, Viral. Herpesvirus 4, Human / genetics. Humans. Interleukin-18 Receptor alpha Subunit. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / metabolism. Lymphoma, AIDS-Related / virology. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / virology. Protein Subunits / biosynthesis. Protein Subunits / metabolism. Receptors, Interleukin-18. Viral Proteins. Viral Structural Proteins / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15498855.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBNA-2 protein, Human herpesvirus 4; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / IL18R1 protein, human; 0 / Interleukin-18 Receptor alpha Subunit; 0 / Protein Subunits; 0 / Receptors, Interleukin; 0 / Receptors, Interleukin-18; 0 / Viral Proteins; 0 / Viral Structural Proteins
  •  go-up   go-down


77. Wong KH, Lee SS, Chan KC: Twenty years of clinical human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in Hong Kong. Hong Kong Med J; 2006 Apr;12(2):133-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many